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Cardiovascular disease secondary to atherosclerosis is the leading cause of death worldwide. 
The pathophysiology of atherosclerosis is multifactorial and complex. This thesis offers insight 
into the regulation of several potential biomarkers of cardiovascular disease and explores the 
effects of anti-platelet therapy in modulating these pathways. 
 
CD14highCD16+ monocytes are elevated in patients with atherosclerosis and may be predictive of 
future cardiovascular events. The initial study in this PhD project assessed the effects of anti-
platelet drugs on the phenotype of circulating monocytes in 60 healthy volunteers in the 
presence of mild, systemic inflammation induced by the influenza immunisation. A significant 
rise in circulating CD14highCD16+ monocytes developed following immunisation and anti-platelet 
therapy was subsequently shown to exert an immunomodulatory action by counteracting this 
response.  
 
Netrin-1 is a laminin-like protein that is implicated in cardiovascular disease, including coronary 
artery disease. A series of experiments were performed to investigate the biomolecular 
mechanisms that regulate the synthesis of vascular netrin-1 in humans. Results showed that 
netrin-1 levels are directly modulated by changes in the production of vasoactive 
cyclooxygenase-derived molecules, such as prostaglandin E2, from the vascular endothelium. 
 
Oxidised low-density lipoprotein was the final biomarker that was investigated. Results 
indicated that CD16+ monocytes may regulate the clearance of oxidised lipoproteins and their 
systemic accumulation, possibly through the internalisation of circulating oxLDL / IgG 
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1.1. The role of inflammation in atherosclerosis 
Cardiovascular disease secondary to atherosclerosis is now the leading cause of death 
worldwide 1. The pathophysiology of atherosclerosis is multifactorial and complex. This thesis 
will explore the inflammatory pathways that contribute to atherogenesis and assess the anti-
atherogenic effects of anti-platelet drugs in patients with silent atherosclerosis.  
 
1.1.1 Atherogenesis 
Atherosclerotic plaques develop over many years and frequently go unnoticed until a patient 
develops symptoms of ischaemia. The lesions typically develop in areas where there is a 
substantial change in blood flow velocity. The first stage of atherosclerosis occurs when serum 
lipoproteins accumulate within the arterial intima creating a state of chronic inflammation. The 
intimal cells become increasingly hypoxic as the arterial wall thickness increases. Monocytes are 
recruited to the subendothelial layer where the initial lesion, known as a fatty streak, develops. 
The monocytes differentiate into macrophages, which phagocytose the modified lipoproteins, 
in particular oxidised low-density lipoprotein (oxLDL) and form foam cells. Foam cells 
accumulate over time and aggregate into a necrotic, atheromatous core within the lesion. The 
plaque reduces the diameter of the vessel lumen, impairing arterial flow. Hypoxic conditions 
develop within the plaque and subsequent neovascularisation develops, increasing the 
likelihood of plaque haemorrhage. As the lesion increases in size, the endothelial shear stress to 
which it is subjected will rise accordingly.  If the plaque ruptures, the lipid-rich contents of the 
atheromatous core are released and the subendothelial layer is exposed. Both plaque-bound 
and circulating blood-borne tissue factor bind to, and activate, factor VII, initiating the clotting 
cascade and thus platelet activation and aggregation. Platelets adhere to the ruptured lesion, 
enhancing the production of platelet agonists, thrombin and thromboxane A2 (TXA2). Further 
platelet recruitment occurs and thrombus formation develops along with vasoconstriction of 
the already compromised vessels. Significant vessel occlusion will result in organ ischaemia and, 


















































































































































































1.1.2 Inflammatory pathways associated with atherosclerosis 
The ‘Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating 
Rosuvastatin’ (JUPITER) study identified that elevated levels of high-sensitivity C-reactive 
protein (hs-CRP), a hepatically synthesised biomarker of inflammation produced in response to 
macrophage-derived interleukin-6  (IL-6), were associated with cardiovascular events, including 
MI and stroke in patients with no previously known cardiac disease 4 5. Hs-CRP was found to be 
a stronger predictor of cardiovascular disease than the traditionally used low-density lipoprotein 
(LDL) levels, demonstrating the importance of underlying inflammation in the development of 
cardiovascular disease. Hs-CRP, however, is a non-specific acute phase response protein, and 
rises in most pathologies where an inflammatory response is generated, including malignancy, 
auto-immune disease, late-stage pregnancy and bacterial infection.  Hs-CRP has yet to be 
causally related to coronary heart disease and a reduction in baseline levels has not been proven 
to improve prognosis 6 7. 
Patients with chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory 
bowel disease have an increased risk of developing cardiovascular disease in later life, 
suggesting a possible link between inflammatory processes and atherogenesis 8. Pro-
inflammatory biomarkers have been shown to have significant prognostic value in MI 9, and a 
recent clinical trial has also identified potential benefits arising from administration of an anti-
inflammatory therapy (colchicine) in the management of acute ST-segment elevation MI (STEMI) 
10. This thesis will focus on three novel inflammatory biomarkers: intermediate CD14highCD16+ 
monocytes, netrin-1, and oxLDL, addressing their role in the development of cardiovascular 
disease and whether anti-platelet therapy can modify their expression. 
 
1.1.3 Oxidised low-density lipoprotein in atherosclerosis 
Clinical evidence has shown that dysregulation of the innate and adaptive immune systems 
occurs during atherogenesis, which is typically accompanied by accumulation of pro-
immunogenic factors, such as oxLDL, that are able to activate innate cell effectors (primarily 
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myeloid cells), subsequently leading to an adaptive immunological response with production of 
circulating autoantibodies (Immunoglobulin (Ig) M and IgG anti-oxLDL antibodies). Classical risk 
factors for cardiovascular disease are poorly correlated with the levels of these immunological 
mediators and thus the question arises as to whether pharmacological targeting of oxLDL and 
its autoantibodies, or reducing monocyte/macrophage activity, may represent a viable strategy 
to improve treatment in patients with cardiovascular disease.  
To date, LDL has been among the preferred therapeutic targets, and drugs such as 3-hydroxy-3-
methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) that reduce circulating 
oxLDL levels are prescribed abundantly in both primary and secondary prevention of 
cardiovascular disease. New immunomodulatory agents continue to be developed in order to 
reduce levels of circulating oxLDL, by either reducing synthesis of oxLDL, such as can occur with 
certain phospholipase A2 inhibitors 11 12, or increasing clearance of the molecules via passive 
immunisation strategies to shift the synthesis of anti-oxLDL autoantibodies away from IgM 
production and in favour of IgG that is thought to be protective 13 14. The effectiveness of these 
therapeutic strategies remains to be defined and whilst several lipoprotein-associated 
phospholipase A2 inhibitors have entered Phase III clinical trials, they have yet to demonstrate a 
significant reduction in cardiovascular events when used alongside conventional 
pharmacotherapy 15 16. Immunisation agents are still at the pre-clinical stage of development 
and further definition of their therapeutic potential is required 17. Characterisation of the 
modulatory effect of conventional therapy on oxLDL-induced immunological dysfunction may 
promote further advance in this field. 
Previous work by our group has demonstrated inflammation can lead to a change in the 
phenotype of circulating monocytes in terms of their expression of the CD16 molecule 18. This 
latter acts as a Fc ϒ receptor for IgG antibodies 19 and as such may mediate the phagocytosis of 
immune complexes consisting of IgG-opsonised oxLDL, thus contributing to their clearance and, 
in turn, regulating accumulation of pro-immunogenic LDL 20. Evidence has also emerged that 
21 
 
myeloid CD16 directly binds to oxLDL via the specific recognition of malondialdehyde (MDA) 
epitopes contained in modified lipoproteins by the Fc ϒ receptor 21.  
Expansion of the CD16+ monocyte pool occurs in the peripheral blood of patients with 
cardiovascular disease 22 23; whether this occurrence has pro-atherogenic implications or is 
rather a protective mechanism potentially implicated in the detoxification of the blood from 
oxLDL is unknown. 
 
1.1.4 Immunisation as a model of inflammation 
Over recent years, immunisation has become a well-established model to study the response to 
mild stimulation of the inflammatory system 24 25, and has been shown to generate a similar 
acute phase protein response to that of chronic systemic inflammatory conditions, such as 
rheumatoid arthritis 26. Salmonella typhi immunisation, in particular, has been used to 
investigate cardiovascular physiology, where the widespread inflammation induced by the 
immunisation causes profound dysfunction of the arterial endothelium in healthy volunteers, as 
evidenced by impaired vasodilatation in response to both physical and pharmacological dilator 
stimuli 27 28. These generalised inflammatory changes post-immunisation may be modified by 
systemic pre-treatment with aspirin, although locally administered aspirin is unable to reverse 
established immunisation-induced endothelial dysfunction 29. 
In 2004, Posthouwer et al showed that influenza immunisation can serve as an in vivo model to 
investigate a generalised pro-inflammatory state. Using healthy subjects, they demonstrated 
that following influenza immunisation, there is a consistent elevation in the inflammatory 
biomarker CRP 30. The same model was subsequently used to identify that acute inflammation 
leads to higher circulating levels of activated platelets and to formation of monocyte-platelet 
aggregates (MPA), which in turn promotes expansion of the CD14highCD16+ monocytic subset 31. 
A subsequent study to assess endothelial function, as measured by flow-mediated 
vasodilatation and soluble intracellular adhesion molecule-1 (ICAM-1) levels, in patients with 
human immunodeficiency virus infection undergoing either influenza A or sham immunisation 
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identified that the active immunisation cohort developed a leucocytosis, indicative of systemic 
inflammation, as well as impaired endothelial function 32. 
Acute infections, particularly with the influenza virus, are strongly associated with 
cardiovascular events 33. Despite the transient pro-inflammatory response generated post-
immunisation, influenza immunisation does not appear to increase the frequency of 
cardiovascular events in the short-term, and has consistently been shown to protect against MI 
in the medium to long-term 34 35. Patients with cardiovascular disease in both the UK and the 
USA are advised to undergo influenza immunisation on an annual basis 36 37. 
It is unclear whether anti-platelet therapy is able to modulate the effectiveness of the immune 
response following vaccination. Current guidelines advise against the use of paracetamol or 
ibuprofen in children post-immunisation as it is generally accepted that the use of antipyretics 
may result in a blunted immune response 38 39. Indeed, COX-2 function is a major determinant 
of antibody synthesis and both aspirin and ibuprofen have been shown to reduce IgM and IgG 
synthesis in human peripheral blood mononuclear cells 40. It would therefore stand to reason 
that aspirin use may reduce the effectiveness of immunisation against influenza and other 
infections, although a randomised controlled trial assessing the development of antibodies 
against influenza subtypes A and B post-vaccination in elderly participants taking either aspirin 
or a placebo showed that aspirin actually augmented the immune response, with higher levels 
of specific antibodies directed against influenza being generated 41. To date, there has been 




Platelets, otherwise known as thrombocytes, are approximately 2.5 μm anuclear, disc-shaped 
cytoplasmic fragments whose primary physiological function is to contribute to haemostasis 42, 
although they play further roles in inflammatory processes. Platelets are derived from 
megakaryocyte precursor cells, which are present within the bone marrow. Thrombopoietin, a 
23 
 
glycoprotein growth factor, is the primary regulator of megakaryocyte production and 
development, alongside numerous cytokines and hormones. As megakaryocytes mature, they 
enlarge to allow high concentrations of ribosomes to accumulate, from which platelet-specific 
proteins will eventually be formed 43. Although this process has not been fully elucidated, in vitro 
data suggest that pseudopodial elongations, termed proplatelets, emerge from the mature 
megakaryocyte, and platelets are budded off from the ends of these processes 44. Each 
megakaryocyte can release thousands of platelets, which enter the systemic circulation or are 
reserved within the spleen 43. Circulating platelets have a life span of 8-10 days, and are typically 
present at a concentration of 150-400 x109 per litre of blood 45.  
The platelet structure is maintained by a complex actin cytoskeleton formation, while the cell 
surface is covered by invaginations of the plasma membrane forming a network of tubes termed 
the open canalicular system 46. This allows substances to be transported from the surface to 
within the platelet, whilst additionally providing a mechanism of secreting storage granules 47. 
The open canalicular system, along with the surface membranes of platelet storage granules, 
allows a 2-4 fold increase in platelet surface area 48. 
There are three main classes of storage granules within platelets. The most abundant, and most 
thoroughly characterised, are the alpha granules, which contain hundreds of soluble proteins, 
including: 
1) Haemostatic proteins, such as fibrinogen and von Willebrand factor.  
2) Coagulation factors, including Factors V, XI, and XIII. 
3) Cellular adhesion molecules, including P-selectin and CD63. 
4) Cytokines, including platelet-factor 4 and chemokine (C-C motif) ligand 5 (CCL5). 
5) Growth factors, including vascular endothelial growth factor (VEGF), platelet-derived growth 
factor (PDGF), and insulin-like growth factor (IGF) 48. 
Additionally, there are delta (also known as dense) granules, which contain platelet activation 
factors, such as adenosine diphosphate (ADP), adenosine triphosphate (ATP), serotonin, 
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histamine, and ionised calcium 49. Lysosomal granules contain hydrolytic enzymes, which are 
released upon platelet activation 50.  
 
1.2.1 Platelet activation and function 
The classically described function of platelets is to prevent haemorrhage. In the presence of an 
intact, healthy endothelium, circulating platelets remain in a resting state. Platelets move into 
an activated state in response to several factors that signal vascular trauma, whereby they 
adhere to damaged endothelium and locally mediate both thrombotic and inflammatory events 
via the secretion of cytokines and interaction with leucocytes. This results in chemotaxis and the 
development of an inflammatory milieu within the arterial wall.  
When endothelial damage has occurred, the extracellular matrix is exposed and collagens are 
released. Collagens stimulate a change in the conformation of platelets, which change from a 
discoid shape to a spherical one, and develop dendritic pseudopodia 51. The collagens bind to 
von Willebrand factor, which interacts with glycoprotein Ib/V/IX, a transmembrane protein 
complex on the surface of platelets that mediates the tethering of activated platelets to the site 
of vascular injury 52-55. The collagen receptor, glycoprotein VI, is also expressed on the platelet 
surface and binds to collagen to induce the release of secondary platelet agonists, including 
TXA2, ADP, thrombin, and adrenaline, which serve to stimulate further autocrine and paracrine 
platelet activation 54.  
Platelet agonists act on G-protein coupled receptors, including those linked to the Gq, G13, and 
Gi proteins, to activate the platelet integrin, glycoprotein IIb/IIIa 56. This receptor mediates 
platelet adhesion via binding to fibrinogen and forming bridges between platelets. A 
haemostatic platelet plug subsequently develops, which increases in size as further platelet 







Thrombin forms a key part of the initiation of the coagulation cascade, and is produced upon 
cleavage of prothrombin by activated factor Xa. Thrombin acts as a serine protease to convert 
fibrinogen to fibrin, which subsequently polymerises into multimeric strands to create a mesh 
that, along with platelets, forms the haemostatic plug 57. Thrombin additionally converts factor 
XIII to XIIIa, which induces the formation of covalent cross-links between the fibrin strands, thus 
further stabilising and strengthening the clot 58.  
Thrombin binds to protease-activated receptors on endothelial cells, activating the cells and 
thus promoting platelet adhesion and cytokine release, and triggering endothelial cell 
production of platelet-activating factor 59. Thrombin can additionally modify vascular tone by 
direct and indirect effects on vascular smooth muscle cells and post-capillary vessels 60-62, 
partially via the promotion of Ca2+ release from intracellular stores and Ca2+ influx across the 
plasma membrane 63. This is of particular clinical relevance in the context of subarachnoid 
haemorrhage, where thrombin accumulates at the site of the bleed and amplifies cerebral 
vasospasm; the contractile response to thrombin is then typically augmented by the 
upregulation of protease-activated receptor-1 (PAR1) 64. 
 
1.2.1.2 Adenosine diphosphate 
ADP is a platelet agonist that interacts with platelet purinergic P2 receptors, including P2Y1, 
P2Y12, and P2X1 65. Upon binding to ADP, platelets undergo a conformational change, developing 
a spiculated, spherical shape, enabling the release of granular contents (containing additional 
ADP) and thus further potentiating platelet aggregation 66 67. As with thrombin, ADP enhances 
intracellular stored Ca2+ release through inositol phosphate production and rapid calcium influx 
via the plasma membrane 65. The P2Y1 Gq-protein coupled receptor mediates the platelet 
structural changes, mobilises calcium, and stimulates the phospholipase C and inositol 
phosphate signalling pathways. P2Y12 is a Gi-protein coupled receptor that blocks adenylyl 
cyclase signalling and reduces intracellular cyclic adenosine monophosphate (cAMP) levels. The 
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fall in cAMP inhibits phosphorylation of vasodilator-stimulated phosphoprotein, which 
subsequently induces activation of the GP IIb/IIIa receptor and platelet aggregation 68. P2X1 
functions as a ligand-gated ion channel, allowing rapid calcium influx upon binding of ADP 67. 
Patients with abnormal storage and release of ADP from dense granules typically present with 
prolonged bleeding times due to impaired platelet aggregation 69.  
 
1.2.1.3 Thromboxane A2 
Binding of ADP to P2Y12 stimulates phospholipase A2-induced release of arachidonic acid (AA) 
from phospholipid. AA is converted to prostaglandin (PG) G2 by cyclo-oxygenase-1 (COX-1), 
which is then reduced by a peroxidase to PGH2 and subsequently converted to TXA2 via TXA2 
synthase 65 66. The thromboxane/PGH2 receptor is present on platelets, as well as monocytes, 
erythrocytes and endothelial cells. TXA2 binds to the thromboxane/PGH2 receptor, which has 
two main isoforms: the Gq-coupled TP, and the Gi-coupled TPβ receptors. These two receptors 
differ in their C-terminal cytoplasmic domains 70, with the TP isoform primarily being expressed 
on platelets 71.  
TXA2 binding to the TP receptor leads to activation of both Gs and Gi proteins, with consequent 
activation of both phospholipase C and adenylyl cyclase, whilst its binding to TP results in Gi 
activation and consequent inhibition of adenylyl cyclase; the net result in platelets being their 
activation leading to the abovementioned conformational changes and aggregation 72. A series 
of experiments using transfected cell lines, showed that TXA2 binding to the TPα receptor 
stimulated adenylyl cyclase and thus increased cAMP formation, whilst opposite effects were 
seen with the TPβ receptor 73.  
Aside from platelet activation, TXA2 plays roles in atherogenesis, vascular remodelling, and 
immunogenicity 74 75, and is a potent vasoconstrictor 76. TXA2 increases the expression of 
endothelial adhesion molecules, such as ICAM-1 and vascular cell adhesion molecule-1 (VCAM-
1), and plays complex roles in endothelial cell migration 75. Mutations in the TP receptors result 
in a varied clinical picture, ranging from impaired haemostasis when reduced receptor activity 
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is present to predisposition to thrombosis and infarction 77 78. Due to the short half-life of TXA2, 
its metabolite, 11-dehydro TXB2 is commonly used when measured in urine as an indirect 
measure of TXA2 79.  
 
1.2.2 Anti-platelet agents 
Anti-platelet agents act via a variety of mechanisms to inhibit platelet aggregation. They are the 
cornerstone of treatment in cardiovascular disease and are used prophylactically in patients 
with significant atherosclerosis who are at risk of thrombotic events. Anti-platelet agents, 
particularly aspirin, have been used for decades and the drug class continues to evolve as novel 
agents with increasingly efficacious anti-platelet actions are identified. The main risk associated 
with all forms of anti-platelet therapy is bleeding, and physicians need to carefully weigh the 
possible adverse effects against the benefits of prescribing these drugs to patients with 
cardiovascular disease. Aspirin, which has been recognised to have anti-thrombotic effects since 
the 1960s, continues to be prescribed almost ubiquitously for patients with acute coronary 
syndrome (ACS), and P2Y12 antagonists are now often added in; such dual anti-platelet therapy 
(DAPT) confers greater anti-thrombotic efficacy but at the risk of increased bleeding. Over recent 
years, it has become apparent that these drugs may also exert powerful anti-inflammatory 
effects that provide additional benefit in the management of ACS.  
Anti-platelet therapy may improve outcomes not only through anti-thrombotic properties but 
also via their anti-inflammatory effects, although their relative contribution in this context 
remains a subject of debate. What is clear, however, is that increased anti-thrombotic efficacy 
improves outcomes post-ACS, but carries the price of increased bleeding risk, so that at some 
point diminishing returns accrue from ever more efficacious anti-platelet therapy. The challenge 
for the future is to better predict the benefit / risk ratio in individual patients, so that the 
intensity of anti-platelet therapy can be optimised on a personalised basis. The following 




1.2.2.1 Cyclo-oxygenase enzymes and eicosanoids 
The COX enzyme converts AA to PGs. There are 2 human isoforms – COX-1, which is expressed 
in most tissues and COX-2, which is typically present in areas of active inflammation 80. As 
mentioned above, the COX enzyme converts AA into PGG2, which is subsequently reduced to 
PGH2 81.  
Eicosanoids are a large group of signalling molecules derived from AA, including PGs, TXs, and 
leukotrienes; of these, prostacyclin (also known as PGI2) and TXA2, are important in maintaining 
platelet homeostasis. Prostacyclin inhibits platelet activation while TXA2 increases platelet 
activation. PGE2 is among the most abundantly expressed eicosanoids and plays complex and 
often contrasting roles in the modulation of inflammation, from initiation of pyrexia to 










Figure 1.2: Cyclo-oxygenase dependent pathways 
The figure shows the conversion of arachidonic acid to prostaglandins, prostacyclin, and thromboxane 









Aspirin, otherwise known as acetylsalicylic acid, irreversibly inhibits both COX enzymes through 
acetylation of a critical serine residue, although its effect on COX-1 is at least ten fold greater 
than that on COX-2 80. By predominantly inhibiting COX-1, TXA2-induced platelet activation and 
aggregation are blocked 84. Aspirin achieves maximum platelet inhibition within 2 hours 
following a loading dose and inhibits aggregation in circulating platelets for at least 5 days 85 86. 
There has been some debate over the past decade as to whether aspirin resistance is a clinically 
significant issue, requiring patients deemed to be ‘poor responders’ to switch to an alternative 
anti-platelet agent 87 88. It has since been shown that whilst platelet function assays may produce 
variable results, and thus suggest that aspirin resistance is present, platelet COX-1 activity, as 
reflected by TXA2 levels, is uniformly and persistently suppressed by low-dose aspirin 89 and it is 
now generally accepted that true pharmacological resistance to aspirin is rare 90. 
The analgesic and topical antiseptic properties of salicylates have been recognised since at least 
3000 BC, with the Ancient Egyptians and Sumerians documenting the medicinal benefits of 
willow and other salicylate-rich trees and plants, such as meadowsweet 91. Hippocrates 
prescribed willow tea to labouring women to relive pain in the fifth century BC 92 and the Roman 
encyclopaedist, Aulus Celsus, documented the anti-inflammatory effects of willow leaf in his De 
Medicina treatise in the first century AD 93.  
 Acetylsalicylic acid was initially synthesised by Charles Frédéric Gerhardt in 1853 94 and 
subsequently marketed as a commercially available drug in 1899 by the Bayer pharmaceutical 
company. The drug was named ‘aspirin’, with the ‘a’ representing the acetyl group that was 
added to salicylic acid to create the drug, the ‘spir’ deriving from the plant, Spiraea ulmaria, from 
which the salicylates were isolated, and ‘in’ being a common suffix for drugs at the time 95. The 
drug achieved prominence in the Spanish influenza pandemic of 1918 and remained 
unchallenged in its position as the leading analgesic agent until the 1950s, when paracetamol 
was brought to the market.   
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Alongside its analgesic and antipyretic effects, aspirin has been recognised as an inhibitor of 
platelet function for around 50 years 96 and, to date, remains the most commonly prescribed 
drug worldwide 97. The pharmacologists, John Vane and Priscilla Piper, established that 
administration of aspirin impaired the production of a compound that they termed ‘rabbit aorta 
contracting substance’ 98 99. Vane later identified this compound as a PG 100 101, finally elucidating 
aspirin’s mechanism of action, for which he was awarded the ‘Nobel Prize in Physiology and 
Medicine’ in 1982.  
 
1.2.2.2 Adenosine diphosphate receptor antagonists 
Clopidogrel, prasugrel and ticagrelor are all ADP antagonists, a class of therapeutic agents that 
bind selectively to the P2Y12 receptor to inhibit platelet function 102. The thienopyridine, 
ticlopidine was the first drug in this class but is seldom prescribed now, following reports of 
serious adverse reactions, in particular neutropaenia 103 and thrombotic thrombocytopaenic 
purpura 104.  
 
1.2.2.2.1 Clopidogrel 
The second generation thienopyridine prodrug, clopidogrel, is currently the most commonly 
prescribed ADP receptor antagonist. It is administered orally and up to 85 % of the absorbed 
drug undergoes hepatic metabolism by carboxyl esterases to form an inactive carboxylic acid 
derivative, clopidogrelic acid, whilst the remaining 15 % is metabolised into the active thiol 
product by cytochrome P450 isoenzymes 102 105; see Figure 1.3. Although clopidogrel has a 
relatively short half-life of 6 hours 106, the thiol metabolite covalently binds to the P2Y12 receptor, 
inducing an irreversible conformational change in the receptor and thus impairing thrombotic 
function for the remaining lifespan of the affected platelet. Genetic polymorphisms in 
cytochrome P450 enzymes, particularly CYP2C19 and CYP2C9, may result in impaired generation 
of the active thiol metabolite in patients taking clopidogrel, resulting in lack of efficacy 107. 
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Variable responses to clopidogrel may additionally result from mutations in the ABCB1 gene that 
encodes the P-glycoprotein involved in clopidogrel absorption 107. 
The standard dosing regime is a 300 mg loading dose and 75 mg daily maintenance dose. 
Following this, steady state ADP inhibition is typically achieved within 3-7 days, with a 40 – 60 % 
reduction in ADP-induced platelet aggregation from baseline 106. Randomised controlled trials 
have demonstrated that clopidogrel is more effective than aspirin in preventing cardiovascular 
events in patients with vascular disease 108, further reduces mortality in patients with MI when 
used alongside aspirin 109, and improves outcomes in patients undergoing PCI when used in 
combination with aspirin 110 111. The ‘Clopidogrel versus Aspirin in Patients at Risk of Ischaemic 
Events’ (CAPRIE) study showed that clopidogrel administration was associated with similar 
adverse effects to those observed with aspirin, including gastrointestinal discomfort and 
increased bleeding, but the overall safety profile of clopidogrel 75 mg daily was considered to 
be least as good as that of aspirin 325 mg daily 108. However, the inter-patient unpredictability 
in clopidogrel responsiveness (with some patients not responding at all) due to the 






























Prasugrel is an oral thienopyridine prodrug that is hydrolysed by esterases to the metabolite, R-
95913. This inactive metabolite is then activated by cytochrome P450 enzymes, forming the 
active metabolite R-138727; Figure 1.4. As with clopidogrel , the active metabolite subsequently 
binds irreversibly via a covalent bond to the platelet P2Y12 receptor and thus inhibits platelet 
function 112. 
A loading dose of 60 mg is given, followed by 5 – 10 mg daily maintenance dosing 113. Peak 
plasma concentration is reached within 30 minutes and the drug has a half-life of 7 hours 112. 
Phase I and II studies have demonstrated that prasugrel has a faster onset of action than 
clopidogrel, as well as being more efficacious and more predictable in its anti-platelet action 114-
116.  The TRITON-TIMI 38 phase III study found that, in patients with ACS undergoing PCI, 
prasugrel was more effective than clopidogrel in reducing further ischaemic events although it 
conveyed a higher risk of major bleeding 117. Further analysis of a subgroup of patients with 
STEMI undergoing PCI found that prasugrel was more effective than clopidogrel in preventing 
additional cardiovascular events without any increased risk of minor or major bleeding 118. 
Among patients with ACS without ST-elevation who did not undergo PCI, prasugrel was not 


























Unlike clopidogrel and prasugrel, ticagrelor is a cyclo-pentyltriazolo-pyrimidine ADP antagonist 
that has distinct pharmacokinetic and pharmacodynamic properties. Ticagrelor binds directly to 
the P2Y12 receptor and alters its conformation, resulting in reversible inhibition. The drug does 
not require metabolic activation and thus exhibits a comparatively rapid onset and offset of 
effect, necessitating comparatively frequent dosing to achieve steady ADP inhibition 120. Plasma 
levels of ticagrelor peak at 1.5 – 3 hours post-ingestion and reach steady state after 2 – 3 days 
121. Although metabolic activation is not required for initiation of its anti-platelet effects, the 
drug does have an active metabolite, AR-C124910XX, which is produced following the 
interaction of the parent drug with cytochrome P450 120 121. 
Ticagrelor is administered as a loading dose of 180 mg, followed by maintenance dosing of either 
60 or 90 mg twice daily. The ‘PLATelet inhibition and patient Outcomes’ (PLATO) study showed 
that ticagrelor was superior to clopidogrel in reducing mortality and further cardiovascular 
events in patients presenting with ACS, regardless of the presence or absence of CYP2C19 and 
CYP2C9 polymorphisms 122. The DISPERSE-2 trial showed that there was no increase in major 
bleeding events in patients with non-ST segment ACS taking ticagrelor compared with 
clopidogrel, however there were significantly more minor bleeding events 123. Ticagrelor 
achieves higher levels of platelet inhibition than clopidogrel 124, likely due to a combination of 
factors, including the aforementioned genetic variations in absorption and metabolism of 
clopidogrel.  
Dyspnoea is a well-documented adverse effect of ticagrelor use, although to date the 
mechanism of this physiological response is unclear, particularly as this is not a prominent 
feature of other drugs in this class. Adenosine activates pulmonary vagal C nerve fibres, inducing 
dyspnoea 125. It has been postulated that ADP receptor inhibition results in higher levels of 
extracellular adenosine, due to drug-induced inhibition of a sodium-independent equilibrative 
nucleoside transporter and subsequent reduced adenosine clearance 126 127.  Although other 
ADP-receptor inhibitors, such as clopidogrel, bind irreversibly to P2Y12 receptors, they have a 
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comparatively short half-life and thus when they inhibit receptors on cells other than platelets, 
such as neurons, their effects are transient as the presence of a cell nucleus allows synthesis of 
new receptors 126. Additionally, twice daily dosing of ticagrelor may result in consistently higher 
plasma drug concentrations compared with other ADP-receptor antagonists that are dosed once 
daily 126.  
In view of the greater platelet inhibition and consequent improved outcomes that are observed 
with prasugrel and ticagrelor compared with clopidogrel, many cardiology centres now 
recommend that the latter is not used as a first line P2Y12 inhibitor in the management of acute 
STEMI 128.  
 
1.2.2.2.4 Cangrelor 
Cangrelor is a novel P2Y12 inhibitor that, like ticagrelor, binds directly to the receptor and induces 
reversible blockade. The drug is a non-thienopyridine adenosine triphosphate analogue that is 
administered intravenously and has shown promising results in clinical trials to date 129. The drug 
has a rapid onset and offset of action, reaches steady state within a few minutes, and achieves 
greater than 90 % inhibition of platelet activation resulting from the P2Y12 pathway 130.  
 In a series of randomised-controlled studies, when compared with current standard therapy, 
however, no significant differences in mortality or further MI were observed when patients were 
treated with either clopidogrel or cangrelor before 131 or during PCI 132. A double-blind placebo-
controlled trial involving 11,145 patients subsequently found that cangrelor significantly 
reduced the rate of ischemic events during PCI, with no increase in severe bleeding, compared 
with clopidogrel 133. At present, cangrelor has been approved by US and European regulatory 
agencies for use in patients undergoing PCI, although it has not yet been recommended by the 
National Institute for Health and Care Excellence (NICE) for use in the UK due to a relative lack 





1.2.2.3 Glycoprotein IIb/IIIa inhibitors 
The platelet integrin complex glycoprotein IIb/IIIa represents the final common pathway of 
platelet activation 56 136. This molecule mediates platelet binding to fibrinogen thereby forming 
bridges between platelets. A haemostatic platelet plug subsequently develops, which increases 
in size as further platelet activation is propagated 56. Glycoprotein IIb/IIIa receptor inhibitors 
block this pathway and thus reduce thrombogenesis. Of the drugs in this class, abciximab (a 
monoclonal antibody fragment), tirofiban (a small, non-peptide molecule), and eptifibatide (a 
cyclic heptapeptide derived from rattlesnake venom) are used in clinical practice 136 137. 
Abciximab additionally binds to integrin receptors on leucocytes and endothelial cells, thus 
reducing the adhesion of platelets to these cells 137.   
Glycoprotein IIb/IIIa inhibitors have played varying roles as anti-platelet agents over the past 20 
years 136. Data from several large-scale meta-analyses looking at glycoprotein IIb/IIIa inhibitor 
clinical trials in the medical management of non-ST-elevation ACS indicate a significant reduction 
in further MI and overall mortality in patients treated with these agents 138 139, and although they 
were  formerly used as key therapies in the management of acute MI for several years, 
glycoprotein IIb/IIIa inhibitors have been gradually phased out in favour of the P2Y12 inhibitors.   
A similar trend has followed with regard to the use of glycoprotein IIb/IIIa inhibitors as 
prophylactic anti-thrombotic agents in patients undergoing PCI, where their use has been 
declining in favour of novel anti-thrombotic / anticoagulant drugs. The TRITON-TIMI 38 study 
found that prasugrel significantly reduced the risk of cardiovascular events in patients with ACS 
after PCI regardless of whether or not a GP IIb/IIIa inhibitor was used concurrently 140. The 
‘Intracoronary Stenting and Antithrombotic Regimen—Rapid Early Action for Coronary 
Treatment’ (ISAR – REACT) trial enrolled 2159 patients with coronary artery disease who 
underwent elective PCI following pre-treatment with clopidogrel 600 mg and either abciximab 
or placebo; there was no observable clinical benefit in those receiving abciximab over the 30 
days post-procedure 141. The ISAR – REACT 2 study subsequently assessed 2022 patients with UA 
or non-STEMI (NSTEMI) undergoing PCI who were pre-treated with 600 mg clopidogrel and 
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either abciximab or placebo, and found that abciximab significantly reduced the incidence of 
adverse events, although only in those patients with elevated troponin levels at presentation 
142. In the UK, current NICE guidance recommends glycoprotein IIb/IIIa inhibitors as an adjunct 
to PCI for all patients with diabetes undergoing elective PCI, and for those patients undergoing 
complex procedures, but not for the routine management of ACS or PCI 143.  
 
1.2.2.4 Dipyridamole 
Dipyridamole is a drug that alters platelet function via two main mechanisms. Firstly, it blocks 
the reuptake of adenosine into platelets, endothelial cells and erythrocytes, leading to increased 
extracellular concentrations of adenosine 144. This stimulates adenylyl cyclase activity, thus 
increasing cAMP levels. The rise in cAMP results in enhanced phosphorylation of vasodilator-
stimulated phosphoprotein and subsequent reduced GP IIb/IIIa receptor activity and platelet 
aggregation 145. Secondly, dipyridamole inhibits the platelet cAMP-phosphodiesterases that 
inactivate cAMP, further augmenting the reduction in platelet aggregation 144.  
Until relatively recently, dipyridamole, used in combination with aspirin, formed the mainstay 
of secondary prevention of ischaemic stroke. Data from the ‘Prevention Regimen For Effectively 
avoiding Second Stroke’ (PRoFESS) study published in 2008 found that there were no significant 
differences in outcome in treating patients with either aspirin plus extended-release 
dipyridamole or clopidogrel, although there were more bleeding events with the dipyridamole 
regime (4.1 % vs 3.36 %; hazard ratio 1.15)  146, and thus the general preference for monotherapy 
over combination therapy has led to a change in guidelines, favouring clopidogrel 147. 
Dipyridamole continues to be used in the secondary prevention of ischaemic stroke in patients 
who do not tolerate ADP-receptor inhibitors, and is frequently prescribed alongside the 
coumarin anticoagulant, warfarin, in the prevention of postoperative thromboembolic events in 






Cilostazol is a quinolinone inhibitor of the phosphodiesterase 3 isoenzyme that, as mentioned 
above, breaks down cAMP, and the drug therefore reduces platelet aggregation. Cilostazol is 
currently licensed for the treatment of intermittent claudication pain in patients with peripheral 
arterial disease, although the main benefits from the drug in this context are derived from the 
vasodilating, rather than anti-thrombotic, effects of elevated cAMP levels 150. Cilostazol is 
currently not recommended for use in patients with peripheral arterial disease in the UK, due to 
its apparent inferiority compared to other vasodilating agents 151.  
Cilostazol may potentially play a role in the future management of transient ischaemic attacks 
and ischaemic strokes. Recent meta-analysis data identified that the drug significantly reduces 
the recurrence of stroke compared to aspirin, with fewer occurrences of intracranial 
haemorrhage than with aspirin, clopidogrel, and DAPT as long-term therapy, although the 
majority of patients involved in these studies were from East Asia and it remains to be seen 

































Figure 1.5: Sites of action for anti-platelet agents 
This figure shows the pathways that are interrupted by anti-platelet drugs to impair platelet activation 
and aggregation. 1) Aspirin acts to inhibit the activity of the cyclo-oxygenase enzyme and thus 
attenuates the production of PGs and thromboxane; 2) The adenosine diphosphate (ADP) receptor 
antagonists bind to the P2Y12 receptor to prevent ADP-induced platelet activation; 3) Glycoprotein 
IIb/IIIa inhibitors impair platelet adhesion by preventing the formation of fibrinogen bridges between 
platelets; 4) Dipyridamole blocks the re-uptake of adenosine into platelets and inhibits the platelet 
cyclic adenosine monophosphate (cAMP)-phosphodiesterases, both of which lead to an increase in 
cAMP levels, thus reducing platelet aggregation; 5) Cilosazol inhibits the phosphodiesterase 3 
isoenzyme that breaks down cAMP.  
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1.2.3 Anti-platelet drugs in primary prevention  
Although guidelines vary throughout the world, it is generally accepted that anti-platelet 
therapy should not be given for primary prevention of cardiovascular disease in patients who 
have no comorbidities. Most physicians use a system, such as the Framingham risk score or the 
QRISK2 score, to calculate a patient’s individual risk of suffering a cardiovascular event based on 
a series of established risk factors before deciding whether the benefit of commencing anti-
platelet therapy outweighs the risks.  
Despite the fact that it is not licensed for this indication, aspirin is usually prescribed as the first-
line anti-platelet therapy in primary prevention in cases where anti-platelet therapy is thought 
to be of benefit154. The British Hypertension Society recommends that aspirin only be used in 
primary prevention in hypertensive patients who are aged over 50 years with 10 year 
cardiovascular risk of at least 20 % 155. In patients with type 2 diabetes mellitus, the current NICE 
recommendations are to consider aspirin therapy in patients who are aged over 50 years, or 
who otherwise have significant cardiovascular risk factors 26. The European Society of 
Cardiology, however, does not recommend the use of anti-platelet agents in primary prevention 
156, based on the findings of a meta-analysis published shortly after the aforementioned NICE 
guidelines, that reported no benefit from aspirin use in preventing major cardiovascular events 
in diabetic patients 157. 
 
1.2.4 The role of anti-platelet drugs in the management of myocardial infarction 
ACS is a term used to encompass unstable angina (UA) and MI with or without 
electrocardiographic (ECG) evidence of ST-segment elevation. Anti-platelet therapy has formed 
the backbone of ACS management for decades and current guidelines recommend that all 
patients routinely receive a loading dose of aspirin, followed by maintenance therapy unless 
contraindicated 158 159. There is a wide range of maintenance dosages of aspirin that are 
prescribed in this context, ranging from 75 to 325 mg daily in different countries 160, although in 
the UK, a loading dose of 300 mg aspirin is given, followed by a daily maintenance dose of 75 
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mg. In patients who have suffered ACS, recommended secondary prevention therapy typically 
entails twelve months of DAPT, followed by lifelong aspirin, whilst patients with stable angina 
are given aspirin monotherapy 36 37. Alongside aspirin therapy, patients with UA or NSTEMI who 
are considered to have a predicted 6-month mortality of greater than 1.5 % (which is the case 
for the vast majority of such patients) are usually treated with a loading dose of 300 mg 
clopidogrel 161. Those with acute STEMIs will go on to receive coronary reperfusion therapy, 
usually with percutaneous coronary intervention (PCI) or, less commonly now, with fibrinolytic 
therapy, and also receive a second anti-platelet agent, namely clopidogrel, prasugrel or 
ticagrelor depending on local guidelines.  
 
1.2.5 The role of anti-platelet drugs in the management of stroke 
NICE guidelines recommend that patients who present with signs of a transient ischaemic attack 
and are considered by the ABCD2 scoring system to have a high risk of stroke are immediately 
offered either 300 mg aspirin or 300 mg clopidogrel (although this would be an off-label use of 
the latter) 28, based on data suggesting that anti-platelet therapy conveys an 80 % reduction in 
the risk of early recurrent stroke 162. 
In the UK, patients who have a confirmed acute ischaemic stroke are typically managed in a 
highly specialist unit where thrombolytic therapy may be given depending on the clinical 
presentation. Otherwise, patients are immediately given 300 mg aspirin to continue for 14 days, 
followed by once daily 75 mg clopidogrel 31. 
 
1.2.6 Dual anti-platelet therapy in coronary artery disease 
DAPT is routinely commenced in patients who have undergone PCI, involving both drug-eluting 
and (more rarely these days) bare-metal stents, with the aim of reducing the risk of subsequent 
in-stent thrombosis. Although the introduction of drug-eluting stents has markedly decreased 
the occurrence of re-stenosis, in-stent thrombosis remains a significant complication. The 
presence of a foreign body within the coronary artery induces platelet adhesion and activation, 
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and potentially thrombus formation, until a layer of endothelial cells has covered the surface of 
the stent. 
Current guidelines recommend that DAPT should be continued for between 6 and 12 months 
post stent-insertion 163 164. Meta-analysis data have generally supported the use of short term 
DAPT (<12 months) regimes, in view of the reduced bleeding rates without an apparent increase 
in ischaemic complications 165-167.  
It is likely that these recommendations will soon be reviewed, following the recent publication 
of results from the ‘Dual Antiplatelet Therapy (DAPT) Study’, a large-scale randomised controlled 
trial, showing that the continuation of DAPT beyond 12 months post-PCI with drug-eluting stent 
placement yielded a reduction in the occurrence of in-stent thrombosis, although there was an 
increased bleeding risk 168. This data has since facilitated the development of a prediction score 
to enable clinicians to identify patients who are likely to receive greater benefit from continuing 
DAPT after 12 months, based on bleeding and ischaemic risk factors, although this has yet to be 
fully validated 169. 
Although a clear consensus on the optimal duration of DAPT post-PCI insertion may take some 
time to reach, a pragmatic approach at present is for clinicians to continue adhering to the 
national guidelines, whilst considering the bleeding and ischaemic risks of their individual 




Table 1.1: Characteristics of anti-platelet drugs 
 
Drug Site of action Time to 
peak 
action 











In Europe loading 
dose 300 mg, 
maintenance 





binds to the P2Y12 
receptor 
45 mins 6 hours Loading dose 300 
– 600 mg, 
maintenance 





irreversibly binds to 
the P2Y12 receptor 
30 mins 7 hours Loading dose 60 
mg, maintenance 










7 hours Loading dose 180 
mg, maintenance 






binds to P2Y12 
receptor 
2 mins 3-6 mins Bolus 30 mcg/kg 






Abciximab Glycoprotein IIb/IIIa 
receptor inhibitor 










































Monocytes are mononuclear white blood cells that play a pivotal role in the human adaptive 
immune response. Monocytes comprise approximately 1-8 % of circulating leucocytes and have 
a half-life of around 1-3 days, after which they move into tissues and differentiate into 
macrophages or dendritic cells 170. Monocytes migrate to sites of local inflammation where their 
roles include phagocytosis and pro- or anti-inflammatory cytokine production. 
 
1.3.1 The role of monocytes in atherosclerosis 
Monocytes play a pivotal role in the development of atherosclerosis via formation and 
deposition of lipid-laden foam cells within the arterial tunica intima, which contribute to plaque 
instability 171. Monocytes are further implicated in the development of atherosclerosis and 
plaque rupture due to their involvement in plaque neovascularisation. As plaque size increases, 
impaired oxygen diffusion develops and the proximal cells of the tunica intima become hypoxic 
172. Cellular oxygen levels become depleted and hypoxia-inducible factor 1 (HIF-1) production is 
upregulated, which induces expression of angiogenic signalling molecules, including vascular 
endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS), which serve to 
enhance the development of adventitial vasa vasorum and intraplaque microvessels 172. 
Monocytes strongly express receptors to VCAM-1, which is produced by intraplaque 
microvessels 173-175. The chronic inflammation present in atherosclerosis triggers increased 
expression of endothelial markers of activation, including VCAM-1, ICAM-1 (also known as CD54) 
and P-selectin (CD62P). There is additional upregulation of monocyte chemoattractant protein-
1 (MCP-1), one of the primary chemokines involved in regulating migration and infiltration of 
monocytes, and its monocytic receptor, C-C chemokine receptor type 2 (CCR2) 176 177.  
Evidence suggests that circulating monocytes may also serve as endothelial progenitor cells, 
further amplifying angiogenesis 173 178. The newly-formed micro-vessels are fragile and prone to 
haemorrhaging. As erythrocytes extravasate from bleeding neo-vessels, their lipid-rich cellular 
contents contribute to further evolution of the atheromatous lesion, while the free haemoglobin 
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potentiates reactive oxygen species (ROS) generation and pro-inflammatory cytokine 
generation 179. Intraplaque haemorrhage is one of the principal determinants of plaque rupture 
180. 
 
1.3.2 Monocyte phenotypes and their differential contribution to atherosclerosis 
Until recently, human monocytes were divided into two major subsets based on their surface 
expression of CD14 and CD16: the CD14+CD16- and the CD14+CD16+ groups. Around 85-90 % of 
monocytes comprise the CD14+CD16- or ‘classical’ group, which are involved in phagocytosis and 
pro-inflammatory cytokine production 177 181. The CD14+CD16+ subgroup has since been 
subdivided into the CD14highCD16+ or ‘intermediate’ group and the CD14lowCD16+ or ‘non-
classical’ monocyte group. The CD14highCD16+ group express the monocyte chemoattractant 
protein-1 receptor, also known as CCR2, which enhances vascular monocyte recruitment and 
their subsequent transendothelial migration 177. CD14highCD16+ monocytes are highly pro-
inflammatory 182 while the CD14lowCD16+group express genes involved in cytoskeletal 
rearrangement and demonstrate high motility and patrolling behaviour 183. See Table 1.2 for 
further details regarding monocyte subsets. There are additional, smaller, poorly-characterised 
subsets of monocytes, including the CD56+ group, which may be associated with certain 












Table 1.2: Monocyte subset characteristics  
 
Monocyte subsets: Classical Intermediate Non-classical 
CD14 expression ++ ++ + 
CD16 expression - + + 
CCR2 expression + + - 
Population % 84.8 183 5.4 183 9.2 183 
Primary functions Phagocytosis 177 
Tissue repair 183 
Immune response 183 
185 
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Prior to the subdivision of the CD16+ monocyte group, it was well-recognised that the CD16+ 
subset was a major producer of serum tumour necrosis factor alpha (TNF-α) in response to 
inflammatory challenges 182. It was subsequently found that CD16+ monocytes were expressed 
at relatively low levels in healthy individuals but showed amplified expression in the presence 
of coronary atherosclerosis, suggestive of a possible role for CD16+ monocytes in atherogenesis 
188. Recently, a correlation between intima-media thickness (IMT) and CD14highCD16+ cell counts 
has been observed 189. 
The association between an increased CD14highCD16+ phenotype and the presence of 
atherosclerosis may be partially explained by the presence of the CCR2 receptor on the surface 
of this particular monotype subset, which regulates the migration and infiltration of monocytes 
190. Our group has previously shown that in the context of acute inflammation the circulating 
CD14highCD16+ numbers expand, and that this cell subset exhibits increased adhesiveness to the 
vascular endothelium 31. 
A multitude of clinical studies have highlighted the association between raised levels of CD16+ 
monocytes and coronary disease. CD16+ monocyte counts were elevated in patients with UA 
compared to matched control subjects with stable CAD. Among the UA patients, those with 
intermediate-high risk of MI had significantly higher counts of the CD14highCD16+ subset 23.  Tapp 
et al found a correlation between CD14highCD16+ counts and peak troponin-T (TnT) levels post-
STEMI, as well as a correlation between CD14highCD16+ counts and left ventricular ejection 
fraction (LVEF) post-STEMI 187. A study by Rogacev et al in 2012 using 951 patients referred for 
elective coronary angiography showed that a higher CD14highCD16+ count was predictive of 
cardiovascular events, including MI, ischaemic stroke and death from all cardiovascular causes 
22.   
Conversely, Jaipersad et al showed that the CD14highCD16-, rather than CD14highCD16+ or 
CD14lowCD16+, subset was predictive of carotid and systemic atherosclerosis severity, and 
intraplaque neovascularisation 173. These differences may be partially explained by the 
heterogeneity of subject groups recruited to the studies, as well as differences in monocyte 
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gating strategies during flow cytometry. Certainly, the majority of studies suggest that the 
CD14highCD16+ subset is highly pro-inflammatory compared with its CD14highCD16-and 
CD14lowCD16+counterparts, and that this subset is strongly associated with the presence of 
cardiovascular disease. Whether CD14highCD16+ levels represent a more specific biomarker of 
cardiovascular risk than hs-CRP remains to be determined. 
 
1.3.3 Monocyte-platelet interactions 
Platelets move from a resting state to an activated state in response to endothelial-derived 
activating factors, such as ADP and thrombin. Activated platelets adhere to damaged 
endothelium and locally mediate both inflammatory and thrombotic events via the secretion of 
cytokines and interactions with leucocytes, which results in chemotaxis and development of an 
inflammatory milieu within the arterial wall.  
Activated platelets form complexes with leucocytes, particularly monocytes, as P-selectin, a 
platelet surface adhesion molecule expressed on platelet plasmalemma upon activation, binds 
to its ligand, P-selectin glycoprotein ligand-1 (PSGL-1) 191 192, which is constitutively expressed by 
circulating monocytes. These MPA are measurable in the peripheral blood and serve as an easily 
quantifiable marker of platelet activation and appear to predict cardiovascular events, such as 
MI 193 and ischaemic stroke 194. Functionally, MPA formed at the site of a vascular injury recruit 
circulating monocytes and facilitate their adhesion to the endothelium, where, following 
adhesion and migration into the subintima, they differentiate to macrophages and contribute 
further to atherogenesis 195. Platelet activation and subsequent MPA formation are increased in 
the presence of high shear stress within blood vessels, such as occurs around the site of 
atherosclerotic lesions 196, and circulating MPA levels in humans correlate with coronary plaque 
size 197. P-selectin levels are independently associated with carotid atherosclerotic lesions in 
humans 198.  
The aforementioned model of acute inflammation, influenza immunisation, has been used to 
demonstrate that acute inflammation leads to higher circulating levels of activated platelets and 
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MPA formation, which promotes expansion of the CD14highCD16+ subset 31. This evidence 
supports the hypothesis that the increased degree of circulating MPA formation reported in 
patients with cardiovascular risk factors or established atherosclerotic disease, could represent 
a key event in the expansion of circulating CD16+ monocytes, which also occurs in the presence 
of cardiovascular disease. Targeting platelet activation could therefore counteract the 
development of the more pro-atherogenic CD14highCD16+ phenotype with a subsequent 
beneficial effect on atherosclerosis progression. Consistent with this hypothesis, previous 
experiments conducted in apolipoprotein knockout (ApoE-/-) mice has demonstrated that 
platelet inhibition, as achieved by either aspirin or clopidogrel administration, counteracts the 
blood monocytosis that accompanies disease progression in this animal model of 
atherosclerosis, thus reducing inflammation 31.  
Although they have no effect on circulating lipid levels, anti-platelet drugs act to disrupt 
pathways in which platelets contribute to atherogenesis, including MPA-driven endothelial 
recruitment of monocytes and thrombus formation in areas of endothelial damage 199 200. The 
pharmacological efficacy of the multiple classes of anti-platelet agents in counteracting anti-
atherogenic mechanisms is variable. Administration of aspirin does not affect circulating levels 
of MPA, whereas clopidogrel appears to impair MPA formation 201 202. Their distinct mechanisms 
of action may have differing effects on the intracellular pathways that finally lead to P-selectin 
expression on activated platelets 203. 
 
1.4. Netrin-1 
Netrins are a class of laminin-like proteins, which were first identified as axonal guidance cues 
during embryonic development 204. The netrin family was named from the Sanskrit word ‘netr’ 
which means ‘one who guides’ 205. Netrin-1 is a secreted protein that mediates axonal 
chemoattractant activity via binding to the deleted in colorectal cancer (DCC) and neogenin 
receptors, and chemorepulsion via the uncoordinated-5 (UNC5) receptors 206-208. 
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The role of netrin-1 in cardiovascular disease and states of acute inflammation is an emerging 
area of research. The identification of DCC and UNC5 receptors on cell types other than neurons, 
has supported the hypothesis that netrin-1 could have additional functions outside the central 
nervous system.  Over the past decade it has become apparent that netrin-1 has involvement in 
multiple physiological responses, ranging from atherosclerosis to inflammation, as well as 
potentially functioning as a marker of renal function (Figure 1.6), making it an attractive 
potential therapeutic target. In recent years, netrin-1 has been identified as a key modulator of 
atherosclerosis, although its precise role in this disease – protective or deleterious – has been 
the subject of much debate. 
 
1.4.1 Netrin-1 in atherosclerosis 
van Gils et al have shown that human macrophage foam cells from human coronary artery 
plaques express netrin-1 and UBC5B, the latter being responsible for the inhibitory effect of 
netrin-1 on macrophage migration that ultimately results in netrin-1 dependent myeloid cell 
retention within plaques 209. In LDLR-/- mice fed a Western diet, deletion of netrin-1 in 
haematopoietic cells reduced atheroma size and complexity and promoted macrophage 
migration from plaques 209. This same group also showed that netrin-1 and UNC5B expression in 
macrophages is upregulated in hypoxic conditions and protects macrophages from apoptosis 210.  
As netrin-1 appears to stimulate progression of atherosclerosis by retaining macrophages within 
atheromatous lesions, thus amplifying the cycle of chronic inflammation, identifying a method 
of interrupting this pathway could prove to be of therapeutic benefit.  
This detrimental effect of netrin-1 on atherosclerosis progression contradicts the evidence 
provided by Khan et al, in which LDLR-/- mice underwent intravenous viral delivery of human 
netrin-1 copy DNA (cDNA) and, when compared with untreated control mice, were found to 
have lower levels of nitrotyrosine (a marker of ROS), as well as of CD68, integrin alpha M 
(ITGAM), and EGF-like module-containing mucin-like hormone receptor-like 1 (EMR-1), all of 
which are markers of macrophage and monocyte activity 211. The netrin-1 treated mice 
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demonstrated a reduction in plaque formation, presumably through the prevention of 
monocytes migrating into atherosclerotic plaques 211 212. Focal application of netrin-1 in this 
situation highlights another potential pathway in atherogenesis where modification of netrin-1 
expression may retard plaque formation. Of note, a reduction in the endothelial expression of 
netrin-1 under pro-atherogenic conditions has been reported by van Gils et al, suggesting that 
suppression of netrin-1 within the vasculature in response to pro-atherogenic factors could 
impede plaque development 209. 
In 2012, Delloye-Bourgeois et al identified that certain cancer cells produce a truncated 
intranuclear form of netrin-1, as opposed to the well-characterised, full-length, secreted netrin-
1 213. The majority of studies prior to this had not differentiated between these isoforms, and it 
has since been postulated that measurement of different isoforms of netrin-1 may explain some 
of the conflicting data surrounding its role in atherosclerosis 203. 
 
1.4.2 The relationship between netrin-1 and inflammation 
Murine models of myocardial ischaemia-reperfusion injury have shown that elevated netrin-1 
expression has a cardioprotective effect, partly achieved by reducing the infiltration of 
neutrophils and recruitment of macrophages that serve to further amplify the pro-apoptotic 
inflammatory response 214 215. Similar results have been shown in models of renal ischaemia-
reperfusion injury 216 as well as other pro-inflammatory states, including acute lung injury, 
peritonitis and sepsis 217 218.  
Both in vitro and in vivo studies have repeatedly demonstrated that netrin-1 and UNC5B 
modulate leucocyte migration in pro-inflammatory states 218. UNC5B is strongly expressed on 
leucocytes and increased netrin-1 expression attenuates leucocyte migration and leucocyte-
driven inflammatory responses 218-220. These findings have generated interest in a potential role 
for netrin-1 in the modification of inflammatory processes.  
Administration of netrin-1 supresses COX-2 expression via regulation of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB). There is a subsequent reduction in COX-2 
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metabolites that mediate neutrophil infiltration, interferon-γ-induced macrophage-activation 
and TXA2 221. Netrin-1 additionally supresses the production of Th1 helper cell cytokines, which 
generate interferon-γ 219. 
The degree to which suppression of the inflammatory response is desirable, and whether this 


























Figure 1.6: Biological roles of netrin-1 
The diverse actions of netrin-1 in cardiovascular and renal disease. Netrin-1 directly modulates survival 
and migration of different cell types, including cardiomyocytes, leucocytes, and endothelial and tubular 
renal cells, through engagement of cell-specific receptors, as indicated. These effects result in netrin-1-
dependent cardioprotection and reduction of kidney damage in response to ischaemia. Netrin-1 also 
confers anti-atherogenic protection, by repelling monocyte arterial infiltration. However, netrin-1-
induced inhibition of resident macrophage egress from atherosclerotic plaques could be detrimental. 
The effect of netrin-1 on neoangiogenesis may be beneficial in the context of cardiac ischaemia but 
detrimental for atherosclerotic plaque destabilization. The anti-inflammatory action of netrin-1 is 
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mediated by direct inhibition of leucocyte motility, as well as by a protective effect on target organs 
that negatively feeds back on inflammatory cell trafficking within the tissue. UNC5B, unco-ordinated-5 
receptor B; DCC, deleted in colorectal cancer receptor; EC, endothelial cells. Figure taken from Layne et 
al., 2015 222. 
 
 
1.4.3 Anti-platelet therapy and netrin-1 
As mentioned above, netrin-1 modulates macrophage migration into and out of plaque sites 209 
and thus represents a potential target for modifying progression of atherosclerosis. In 2015, 
Passacquale et al published a series of experiments where the relationship between endothelial 
netrin-1 expression and anti-platelet therapy was explored using both in vitro and in vivo 
models. They found that aspirin, but not clopidogrel, reduced vascular endothelial permeability 
and increased netrin-1 production in the ApoE-/- mouse model of atherosclerosis, which in turn 
led to reduced monocyte infiltration of atherosclerotic plaques 203. These findings suggest that 
anti-platelet therapy with aspirin may have the potential to modify circulating netrin-1 levels 
and thus modulate atherosclerosis generation. This, together with the previously mentioned 
beneficial effect of platelet inhibition on blood monocytosis observed in ApoE-/- mice, points to 
the existence of a mutual interaction between platelet activity, endothelial chemorepulsion 
against monocyte infiltration, and monocyte phenotype that can be positively modulated by 
anti-platelet strategies.  
 
1.5 Aims 
The aims of this PhD were as follows: 
 Chapter Two: To assess the effects of anti-platelet drugs on the phenotype of circulating 
monocytes in healthy volunteers in the presence of mild, systemic inflammation 
 Chapter Three: To investigate the biomolecular mechanisms that regulate the synthesis 
of serum netrin-1 in humans 
56 
 
 Chapter Four: To explore the role of CD16 in the transduction of the signalling pathways 






























THE EFFECT OF ANTI-PLATELET THERAPY ON 
CIRCULATING CD16+ MONOCYTES  













Circulating human monocytes consist of a heterogeneous cell population generally classified 
into three main subtypes: the ‘classical’ CD14highCD16−, ‘intermediate’ CD14highCD16+, and ‘non-
classical’ CD14lowCD16+ cells 223. The prevalence of these subpopulations in the peripheral blood 
changes under pro-inflammatory conditions, with an expansion of the ‘intermediate’ subset 
typically occurring in the context of atherosclerosis-related inflammation 188. The functional 
implications of such changes in terms of disease progression remain elusive, although a positive 
correlation between the level of CD14highCD16+ monocytes and the presence of subclinical 
atherosclerosis has been demonstrated 189. More importantly, intermediate monocytes have 
proved to be an independent predictive factor for future cardiovascular events 22, and a strong 
correlation between their blood level and coronary plaque vulnerability has been detected 224-
227. This indicates that CD14highCD16+ cells may represent a novel biomarker of cardiovascular 
risk and a potential target for preventative therapeutic strategies.  
In this respect, previous work undertaken by our group suggests that anti-platelet drugs may 
have a modulatory action on the phenotype of circulating monocytes, and additionally that 
platelet activation is a key determinant in the acquisition of a CD16+ profile by human monocytes 
31. Furthermore, using ApoE−/− mice, our group has demonstrated the efficacy of platelet 
inhibition in vivo, as achieved by either aspirin or clopidogrel administration, in counteracting 
the blood monocytosis and expansion of circulating Ly6Clow cells (the murine counterpart of 
CD16+ monocytes) that accompany disease progression in this well-established animal model of 
atherosclerosis 203. In the current clinical study, I have assessed the effect of anti-platelet drugs 
currently used in cardiovascular prophylaxis on the phenotype of circulating monocytes in 
healthy human subjects in the context of a pro-inflammatory stimulus. I have used influenza 
immunisation as an experimental model of acute inflammation, in line with our group’s previous 
report showing an increase in the pool of circulating CD14highCD16+ cells in response to this 
vaccine 31, and also in keeping with other researchers who have previously used immunisations, 
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particularly the seasonal influenza and Salmonella typhi vaccines, in clinical studies to generate 
mild, systemic inflammation and investigate its relevance to cardiovascular pathophysiology 27 
28 30. 
 
2.2 Hypothesis and aim 
Levels of circulating CD14highCD16+ monocytes increase in atherosclerotic patients and are 
predictive of future cardiovascular events. Platelet activation has been identified as a crucial 
determinant in the acquisition of a CD16+ phenotype by classical CD14highCD16− cells. I aimed to 
test the hypothesis that anti-platelet therapy modulates the phenotype of circulating monocytes 
in the context of systemic inflammation. 
 
2.3 Methods 
2.3.1 Participant recruitment 
Seventy five healthy subjects were studied, before and 48 hours after receiving seasonal 
influenza immunisation. Subjects were recruited from workers employed by Guy’s and St 
Thomas’ NHS Foundation Trust (GSTT) who attended the Occupational Health Department 
requesting influenza immunisation. None of the subjects were taking regular medications, aside 
from the combined oral contraceptive pill, and had not taken anti-platelet medication in the 
preceding fortnight. Participants were randomly assigned to receive either anti-platelet therapy 
or no treatment, according to the following scheme: 
- Group 1 (aspirin 300): aspirin 300 mg orally immediately following immunisation and another 
300 mg dose 24 hours later; n = 15. 
- Group 2 (aspirin 75): aspirin 75 mg orally immediately following immunisation and another 75 
mg dose 24 hours later; n = 15. 
- Group 3 (clopidogrel): clopidogrel 300 mg orally immediately following immunisation, with a 
further dose of clopidogrel 75 mg 24 hours later; n = 15. 
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- Group 4 (ticagrelor): ticagrelor 90 mg orally twice daily for 48 hours, the first dose being taken 
immediately following immunisation; n = 15. 
- Group 5 (untreated): no anti-platelet treatment given following immunisation; n = 15. 
I carried out ‘directly observed tablet’ taking with the first dose of each medication for each 
participant. 
 
2.3.2 Influenza immunisation 
The 2014/15 National Health Service (NHS) trivalent seasonal influenza immunisation, an 
inactivated (split virion) vaccination, specifically targeting ‘A/California/7/2009 (H1N1)pdm09-
like virus’, ‘A/Texas/50/2012 (H3N2)-like virus’, and  ‘B/Massachusetts/2/2012-like virus’, 
manufactured by  Sanofi Pasteur MSD Limited, was administered via intramuscular injection into 
the upper arm by a trained healthcare professional, as part of normal Occupational Health 
procedures. 
 
2.3.3 Collection of blood samples 
Blood samples were collected immediately prior to immunisation and again 48 hours later. 16 
ml whole blood was obtained from the antecubital vein using a 23-gauge butterfly needle and 
collected directly into three vacutainer tubes. 
The first vacutainer tube contained a serum gel separator, and blood was left to clot within this 
tube for 10 minutes at room temperature. The blood was centrifuged for 15 minutes, 1500 x g, 
at room temperature to obtain serum that was stored at -80 °C for subsequent analysis.   
The other two vacutainer tubes contained ethylenediaminetetraacetic acid (EDTA). One tube 
was processed by the ViaPath laboratory at GSTT, London, to obtain cell counts using a 
Beckmann DX 7 analyser, while the other was used for subsequent flow cytometry analysis and 
preparation of plasma aliquots for future use. Plasma was prepared by centrifuging the blood 







100 μl whole blood was removed from the EDTA vacutainer tube and incubated with 5 µl of both 
R-phycoerythrin (PE)-mouse anti-human CD14 (BD Bioscience) and fluorescein isothiocyanate 
(FITC)-conjugated anti-human CD16 (3g8 clone, which reacts with both CD16a and CD16b 
isoforms of CD16; BD Bioscience) for 20 minutes at 4 ºC. 1 ml BD FACS lysing solution (BD 
Bioscience) was used to lyse the erythrocytes. The samples were incubated for 10 minutes, 
whilst protected from light, and then centrifuged for 5 minutes, 1500 x g, at room temperature. 
Supernatant was discharged and the pellets were washed twice with 1 ml phosphate-buffered 
saline (PBS) / 0. 2% bovine serum albumin (BSA) / 0.1 % sodium azide. Samples were again 
centrifuged for 5 minutes, 1500 x g, at room temperature, then fixed with 250 µl 1 % 
paraformaldehyde. Immunostaining took place within an hour of the samples being obtained. 
After processing, samples fixed in 1 % paraformaldehyde were stored at 4 ºC for up to 48 hours 
prior to flow cytometry analysis. 
 
2.3.5 Whole blood flow cytometry 
The immunostained samples were analysed using a BD FACSCalibur (BD Bioscience) flow 
cytometer to determine monocyte subset distribution. A total of 100,000 events were acquired 
and post-acquisition analysis was performed using FlowJo (version 10) software.  
Monocytes were identified on a forward (FSC) – versus side scatter (SSC) plot and gated to 
analyse expression of CD14 and CD16 fluorescence, in order to distinguish the different subsets 
of monocytes: “classical” CD14highCD16-, “intermediate” CD14highCD16+ and “non-classical” 
CD14lowCD16+ cells. The percentage of each monocyte subset with respect to total monocytes 
was calculated and absolute numbers were obtained based on the full blood count results. Every 
analysis was performed independently by two blinded researchers (Dr Gabriella Passacquale and 
I).   
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In a subgroup of 10 participants, Dr Gabriella Passacquale repeated measures of monocyte 
subset cell count on 2 consecutive measurements, 2 days apart and before immunisation 
administration, in order to assess variability in monocyte subset cell count in the absence of any 
intervention (immunisation either in the presence or absence of pharmacological treatment). 
Such an analysis showed inter-assay variation of <2 % for all the different monocytic subsets. 
Moreover, our gating strategy for monocyte characterisation (which was based on a FSC-versus 
SSC monocyte profile) was directly compared with a flow cytometry methodology that also 
included the pan-monocytic marker antibody allophycocyanin (APC)-mouse anti-human CD86, 
in the antibody panel 228. In this case, cells with a typical monocytic FSC versus SSC profile and 
positive to CD86 staining were gated to analyse CD14 and CD16 expression.  
Prevalence of the different monocyte subpopulations obtained with the two gating strategies 
were analysed on SPSS (version 23) to calculate the intraclass correlation coefficient (ICC) using 
an absolute agreement definition. The ICCs were 0.961 (95 % CI: 0.859-0.989; p<0.0001), 0.924 
(9 5% CI: 0.711-0.980; p<0.0001) and 0.915 (95 % CI: 0.695-0.977; p<0.0001) for the classical, 
intermediate and non-classical subset respectively; Figure 2.1.  
In order to increase robustness of data, we also analysed the level of CD16 expression on 
monocytes using a normalised median fluorescence intensity (nMFI) strategy, in agreement with 
previously published methods used to monitor changes in cell immunophenotype in repeated 




























Figure 2.1: Flow cytometry analysis 
As a validation study of our methodology, a comparison was carried out between the gating strategy 
for monocytes used in the current study (panel A, technique 1) and the use of a pan-monocytic marker, 
namely CD86, (panel B, technique 2).  
In ‘Technique 1’, monocytes were identified based on their scatter properties using an autogating tool 
(as shown in the FSC vs SSC plot, A1). In ‘Technique 2’, they were initially identified as CD86+ cells using 
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manual rectangular gating (B1) followed by a SSC vs FSC dot plot to further gate monocytes with a 
typical scatter property using an autogating tool (SSC vs CD86 plot, B2). Within the gated populations 
(A2, B3), CD14high and CD14low monocytes were identified, with “high” denoting an expression of CD14 
approximately 100-fold higher and “low” as 10-fold higher than the isotype, as underlined in the 
corresponding histograms. Similarly, positivity for CD16 was evaluated based on the isotype control (in 
grey). The prevalence of each monocyte subset, obtained using a rectangular gating strategy, was 
calculated over the total monocytes. Data (median with IQR) are reported in the graph (C, classical 
CD14highCD16- in black, intermediate CD14highCD16+ in red and non-classical CD14lowCD16+ in blue). A 
high level of concordance between the two strategies was noted, as evidenced by an intra-class 
correlation coefficient (ICC) of 0.961 (95 % CI: 0.859-0.989; p<0.0001), 0.924 (95 % CI: 0.711-0.980; 
p<0.0001) and 0.915 (95 % CI: 0.695-0.977; p<0.0001) for the classical, intermediate and non-classical 
subsets respectively. The correlation analysis (Spearman’s correlation analysis) between the two 
techniques is graphed in D. Both gating strategies enabled restriction of analysis to the CD14+ 
population thus excluding potential interference from cell types such as neutrophils (blue, typically 
CD14-CD16high), and a subpopulation of lymphocytes (green, CD14-CD16low, likely NK cells) that are 
shown in the side panels (A3, A4) and overlaid with the analysed monocytes (black) and isotype control 
(grey).  
Dot plots representative of untreated and treated participants are shown in panels E and F respectively.    
Since significant differences between groups were observed in the prevalence and cell number of 
CD14highCD16- (black) and CD14highCD16+ (red) subsets, the level of CD16 expression was also specifically 
analysed within the CD14high population using a normalised  median fluorescence intensity (nMFI) 
strategy. The histograms (G and H) show overlay of the baseline (empty histogram) and post-
immunisation (filled histogram) intensity of fluorescence for CD16 of the stained samples (red). Also 
shown are the fluorescence levels of the antibody isotype controls (in grey, with dotted histogram and 
filled histogram for baseline and post-immunisation samples respectively). The median fluorescence 
intensity (MFI) calculated in CD14high monocytes at baseline (pre) and post-immunisation (post) were 
normalised by the MFI of the corresponding isotype control as indicated in the figure.   
65 
 
2.3.6 Serum clinical biochemistry 
All serum clinical biochemistry was measured by ViaPath laboratory at St Thomas’ Hospital, 
London. Serum creatinine levels were obtained by using the creatininase enzymatic method on 
a Roche C8000 analyser. Liver enzyme and lipid levels were also measured using a Roche Cobas 
8000 analyser. Hs-CRP was measured using a DadeBehring BN2 analyser. Glycosylated 
haemoglobin levels were measured from whole blood samples using a Menanarini Hb9210 
analyser. All of the aforementioned assays were performed by Viapath staff at St Thomas’ 
Hospital.  
 
2.3.7 Enzyme-linked immunosorbent assays 
Enzyme-linked immunosorbent assays (ELISAs) were carried out to measure plasma levels of P-
selectin using commercially available kits (BEK1189, Biospes), as per manufacturer instructions 
(inter-assay variability was found to be <5 %). 
Briefly, 100 µl of either plasma samples or standards ranging from 0 – 2000 pg/ml were loaded 
in duplicate onto a 96-well plate coated with anti-P-selectin polyclonal antibody. The plate was 
incubated for 90 minutes at 37 ºC. The liquid was then removed from the wells and 100 µl biotin-
conjugated anti-human P-selectin antibody was added to the wells.  The plate was incubated for 
60 minutes at 37 ºC and was then washed three times with wash buffer from the kit. 100 µl 
avidin-biotin-peroxidase complex was added to each well and the plate was incubated for 30 
minutes at 37 ºC. The plate was washed five times and 100 µl 3,3',5,5'-tetramethylbenzidine 
(TMB) was added to each well. The plate was incubated at 37 ºC in the dark for 15-30 minutes, 
until various shades of blue colouration could be detected within the standard wells. 100 µl stop 
solution (typically sulphuric acid, at a concentration of around 0.16 M) was added to each well 
to prevent the reaction from continuing, and the colour was observed to change from blue to 
yellow. The plate was subsequently analysed using a microplate optical density reader at 450 
nm wavelength. A standard curve was constructed by plotting the optical densities of the 
standards against the corresponding known P-selectin concentrations; Figure 2.2. Plasma P-
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selectin concentrations in the different samples were read from the standard curve using the 
respective optical density readings. 
ELISA kits were also used to measure serum levels of CD16a (SEB278Hu; Cloud-Clone Corp.), and 
CD16b (SEB271Hu; Cloud-Clone Corp.) using a similar technique to that stated above, with 
variations based on manufacturer instructions. ELISA kits to measure IL-1β (MBS263843; 
MyBioSource, USA), IL-6 (0Kaa00012_96W; Aviva Systems Biology, USA), and TNF-α (GWV-
SKR066; GenWay Biotech Inc, USA) were used but the cytokine levels in this healthy volunteer 
population were too low to be accurately detected, and thus a Luminex® ultrasensitive cytokine 











Figure 2.2: A representative standard curve from the P-selectin enzyme-linked 
immunosorbent assay 
The optical density reading (at 450 nm) was plotted against the P-selectin concentration to obtain a 





2.3.8 Luminex assay 
A magnetic Luminex® ultrasensitive cytokine multiplex assay (Life Technologies Corporation) 
was performed to measure levels of IL-1β, IL-6 and TNF- in serum. Manufacturer instructions 
were followed.  
Briefly, a custom-made antibody bead solution was vortexed for 30 seconds and then sonicated 
for 30 seconds to prevent the beads from clumping. 25 µl of beads were added to each well in 
a 96 –well plate; the plate was protected from light to prevent photobleaching. The wells were 
washed twice with pre-prepared wash solution (using a handheld magnet underneath the plate 
to keep the beads in place). 50 µl pre-prepared incubation buffer was added to all wells. Either 
100 µl of diluted standards, or 50 µl of assay diluent followed by 50 µl of sample (diluted to 1:100 
with pre-prepared assay diluent) was added to each well and the plate was incubated at room 
temperature for 2 hours on an orbital shaker.  
The liquid was removed and the plate was washed twice. 100 µl biotinylated detector antibody 
was added to each well and the plate was incubated at room temperature for an hour on an 
orbital shaker. The wells were washed twice and 100 µl streptavidin-R-phycoerythrin conjugate 
was added to each well. The plate was incubated at room temperature for 30 minutes on an 
orbital shaker. The wells were washed four times and the plate was subsequently read using a 
Luminex® Flex Map 3D Analyser. 
 
2.3.9 Sample size calculation 
The sample size needed for the study was calculated in accordance with previously published 
data that showed a standard deviation for CD16+ monocytes and total monocytes within a 
healthy population of 5 %, with a difference in means between pre and post-immunisation 
values of 7.5 % 31. Using a minimum detectable difference in means between anti-platelet 
treatments and placebo at the end of the study of 4 %, at power 0.9 and significance level 0.05, 




2.3.10 Statistical analysis 
Statistical analyses were performed using SPSS (version 23) software. A Shapiro–Wilk normality 
test was run for all variables measured in the study. The effect of treatments on monocyte 
subtypes, inflammatory biomarkers (hs-CRP and cytokines), and platelet activation (soluble P-
selectin), which were all found not to be normally distributed, were compared using a non-
parametric analysis of co-variance (rank ANCOVA) with Bonferroni post hoc correction for 
multiple comparison analysis, using baseline values as a covariate. Baseline vs. post-
immunisation comparison of the analysed variables was also analysed within each group by 
Wilcoxon matched-pairs signed-rank test. Associations between variables were assessed by a 
Spearman's correlation analysis. A p value <0.05 was taken as statistically significant. Data are 
expressed as the mean ± standard error of mean (SEM) or median and interquartile ranges (IQR) 
for parametric and non-parametric variables, respectively. 
 
2.4 Results 
2.4.1 Anti-platelet drugs do not influence hs-CRP rise post-immunisation 
General characteristics of the study population stratified across groups are shown in Table 2.1. 
Influenza immunisation induced an acute inflammatory response as evidenced by an increase in 
hs-CRP post-immunisation in all study groups; Figure 2.3. None of the anti-platelet drugs 
modified the rise in hs-CRP in response to immunisation administration; Figure 2.3. 
As above, IL-1β, IL-6, and TNF- levels were measured using a Luminex® assay. There were no 
significant differences between post-immunisation and baseline levels of any of these pro-











































































































































































































Figure 2.3: High-sensitivity C-reactive protein levels 
Panel A: absolute values of hs-CRP pre- and post-immunisation are shown for all groups. Panel B: the 
percentage change from baseline in hs-CRP is shown for all groups. 
 
 











































































































Figure 2.4: Cytokine levels pre- and post- immunisation 
The absolute values for IL-1β (A), IL-6 (B), and TNF-α (C) at baseline and post-immunisation are shown. 
Data are reported as median with IQR. Rank ANCOVA was used for between-group comparison and 
identified no significant differences. 
 
 
Table 2.2: Pre- and post-immunisation levels of hs-CRP and cytokines  
 Hs-CRP (mg/L) IL-1β (pg/ml) Il-6 (pg/ml) TNF-α (pg/ml) 
 Pre Post Pre Post Pre Post Pre Post 


















































































2.4.2 Expansion of intermediate CD14highCD16+ monocytes in response to influenza 
immunisation is attenuated by all anti-platelet treatments 
The baseline monocyte phenotype was similar between groups, with a typical preponderance 
of the ‘classical’ CD14highCD16− subtype (median of 92.7 % of total monocytes) over the 
‘intermediate’ CD14highCD16+ (4.2 %) and ‘non-classical’ CD14lowCD16+ (3.2 %) subpopulations in 
all participants (Figures 2.5-2.6, Table 2.2). Whilst the total monocyte cell count remained stable 
post-immunisation in the whole study population, differences emerged between groups as 
regards the distribution of the different subsets. Results from the participants not treated with 
any anti-platelet drugs showed a significant increase in both percentage (from a median of 3.7 
to 7.8 %; p = 0.0002) and absolute number (from a median of 18.07 to 33.40 cells/µL; p = 0.0002) 
of the CD14highCD16+ subtype; and a concomitant reduction in both the percentage (from a 
median of 91 to 86 %; p = 0004) and cell count (from a median of 443.90 to 399.00 cells/µL; p = 
0.002) of classical CD14highCD16− monocytes was noted. No change in the non-classical 
CD14lowCD16+ population was observed (Figures 2.5-2.6, Table 2.2). 
All of the tested anti-platelet regimes abrogated the above changes in monocyte phenotype 
induced by immunisation. Although no statistically significant differences were observed 
between the treated groups, there was a trend towards aspirin 300 mg exerting a stronger effect 
in limiting the expansion of CD14highCD16+ count post-immunisation (median percentage change 
from baseline was −12.6 in Group 1 vs. +67.3 in untreated; p = 0.0010). Attenuation in the 
CD14highCD16+ increase post-immunisation was also observed in Group 2 (aspirin 75) (median 
percentage increase was 9.3; p = 0.0019 vs. untreated) and, although less pronounced, in Group 
3 (clopidogrel) (median percentage increase was 10.8; p = 0.0024 vs. untreated) and Group 4 
(ticagrelor) (median percentage increase was 16.0; p = 0.0027 vs. untreated). Typical monocyte 

































Figure 2.5: Monocyte subset prevalence 
Graphs A, B and C show the prevalence of each monocyte subset (expressed as percentage over total 
monocytes) at baseline and post-immunisation in the different groups; A = CD14highCD16-, B= 































Figure 2.6: Monocyte percentage change 
The percentage change from baseline of CD14highCD16−, CD14highCD16+, and CD14lowCD16+ cell count in 


























Figure 2.7: Typical monocyte phenotype profile 
Comparison of the typical changes in monocyte phenotype profile in a subject who did not receive anti-
platelet therapy (top images) with one who did (bottom images), showing with an increase in 













2.4.3 The rise in CD14highCD16+ monocytes in response to immunisation is directly correlated 
with CD16 expression  
CD16 expression, specifically analysed within the CD14high population, was studied using the 
nMFI strategy. Group 5 (untreated) showed a significant rise in monocytic CD16 levels post-
immunisation (median percentage change from baseline was +20.92; p = 0.002 vs. baseline) that 
was abolished by all anti-platelet drugs, with aspirin 300 mg daily appearing to be the most 
efficacious of the treatments in this regard (median percentage increase from baseline in Group 
1 was −2.1; p = 0.006 vs. Group 5; in Groups 2, 3 and 4, it was +0.5, +2, and +1.5 respectively; p 
= 0.018, 0.022, and 0.0021 respectively vs. untreated). Likewise, a strong direct correlation was 
found between the increase from baseline of CD14highCD16+ cell count and CD16 nMFI (r = 0.5; 
p = 0.0005) (Figure 2.8). While attenuating the increase in CD14highCD16+ cells, the anti-platelet 
regimes counteracted the reduction in CD14highCD16− monocytes observed in untreated 
participants post-immunisation (Figure 2.9). The two monocyte subsets showed a strong inverse 



















Figure 2.8: CD14highCD16+ cell count and CD16 normalised median fluorescence intensity 
correlation 













Figure 2.9: CD14highCD16+ and CD14highCD16- cell count correlation 






2.4.4 As monocytes acquire a CD14highCD16+ phenotype, there is upregulation of 
polymorphonuclear leucocyte cell surface expression of CD16 
In addition to the observed upregulation of CD16 on circulating monocytes, in Group 5 
(untreated) there was a rise in surface CD16 expression on PMNs in response to the influenza 
immunisation. PMN nMFI increased from 203.50 ± 17.93 to 332.50 ± 54.90 (p = 0.0262). This 
response was counteracted by all anti-platelet drugs, which in fact reduced the level of CD16 
expression on PMNs; see Table 2.3 and Figure 2.10 A.  
When the percentage change in PMN surface CD16 in Group 5 (untreated) was compared to the 
four anti-platelet therapy groups using a multiple comparison analysis, it was found to be 
significantly higher than each of the other groups; see Figure 2.10 A. 
 
2.4.5 As monocytes acquire a CD14highCD16+ phenotype, there is no change in soluble CD16a 
but a reduction in soluble CD16b levels 
As CD16 undergoes shedding, I measured levels of soluble CD16 in serum, using ELISA kits that 
specifically detect either monocyte-derived CD16a or PMN-derived CD16b isoforms.  Soluble 
CD16a levels remained unchanged in all groups; Table 2.3 and Figure 2.10 B. Conversely, soluble 
CD16b concentrations fell from 89.90 ± 11.29 ng/ml to 55.93 ± 7.259 ng/ml post-vaccination in 
Group 5 (untreated; p = 0.0143). This response was counteracted with similar efficacy by all anti-












































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.10: A comparison of CD16 levels between visits 1 and 2 
Figure 2.10 shows a comparison of CD16 levels between visits 1 and 2, including PMN cell surface CD16 
expression (A), measured as MFI with flow cytometry, as well as soluble CD16a (B) and CD16b (C) in 
serum. A multiple comparison analysis is shown for graph A, where the mean of Group 5 (untreated) is 







2.4.6 Modulation of P-selectin is linearly related to the change in monocyte phenotype  
The level of P-selectin post-immunisation in Group 5 (untreated) increased by a median of +17.2 
% (p = 0.039 vs. baseline) (Figure 2.11, Table 2.4). A significant decrease in P-selectin was 
observed in participants on aspirin 300 mg (median percentage change from baseline was -30.7 
% in Group 1; p = 0.003 vs. baseline and p = 0.007 vs. untreated) and aspirin 75 mg (-34.7 % in 
Group 2; p = 0.011 vs. baseline and p = 0.002 vs. untreated). 
Treatment with clopidogrel led to a median change from baseline of P-selectin of 3.3 % (p = 
0.463 vs. baseline and p = 0.388 vs. untreated). Conversely, there was a significant rise in P-
selectin of 16.71 % (p = 0.0335 vs. baseline and p > 0.9999 vs. untreated) among participants 
taking ticagrelor, producing similar results to those in Group 5 (untreated). In a combined 
Spearman’s correlation analysis incorporating all study variables, monocyte phenotype changes 
correlated only with changes in P-selectin. Indeed, the increase in P-selectin values was directly 
correlated with an increase in CD14highCD16+ cell count (r = 0.5; p = 0.0003) and a reduction in 
CD14highCD16- absolute number (r = -0.4; p = 0.001) (Figure 2.12). No relationships emerged 
between P-selectin and any of the other variables analysed in the study population, including 

















Figure 2.11: Post-immunisation change in P-selectin levels for each group 
Figure 2.11 shows the percentage change from baseline of P-selectin in each group. The percentage 




















Figure 2.12: Modulation of P-selectin correlates with change in monocyte phenotype 
Figure 2.12 shows the correlation between change in P-selectin and change in classical CD14highCD16- 
and intermediate CD14highCD16+ monocyte cell count, respectively. 
 
A 
B r = 0.4658 















































Atheroma development in humans is accompanied by systemic immunological abnormalities 
that share homologies with autoimmune diseases 230. In the pathophysiology of atherosclerosis, 
the key contributing factors can be grouped into three main phases: (i) accumulation within the 
artery and in blood of immunogenic self-proteins, i.e. oxLDL derived from exposure to 
cardiovascular risk factors; (ii) consequent activation of innate immune mediators (primarily 
myeloid cells, but recent findings also point towards platelets playing a crucial role) through 
engagement of pattern recognition receptors; and (iii) a subsequent adaptive immunological 
response involving T and B cells 231.  
In this context, influenza immunisation provides a valuable experimental model to study the 
dynamics of monocyte phenotype in response to an immunogenic stimulus. In keeping with a 
previous study by this group 31, the current data confirm that immunisation generates a 
reduction in the proportion of ‘classical’ CD14highCD16- monocytes, which mirrors the increase 
in the ‘intermediate’ CD14highCD16+ subset, in peripheral blood samples from participants not 
receiving anti-platelet therapy. This shift in the profile of circulating monocytes towards a CD16+ 
phenotype mimics the inflammatory response that is characteristically seen in patients with 
atherosclerosis 22 188 189 224-227. Whether this shift in monocyte phenotype has functional 
implications as regards disease progression remains unclear.  
It is worth mentioning, however, that CD16 is an important signalling molecule with a key role 
in the innate response to immunogenic stimuli, in light of its demonstrated involvement in the 
phagocytosis of IgG-opsonised external particles by myeloid cell types that subsequently 
stimulates the adaptive immune system 19 232. Of note, polymorphism of CD16a, which is 
specifically expressed on monocytes, has been reported to influence susceptibility to, as well as 
severity of, CAD 20. Indeed, CD16a genetic variants exhibit distinct affinities for IgG molecules, 
with consequent effects on the efficiency of clearance of circulating immunogenic / pro-
atherogenic factors that would otherwise accumulate within the arterial wall to perpetuate 
inflammation 20. On this background, an increase in circulating CD14highCD16+ monocytes might 
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be regarded as a protective anti-atherogenic mechanism. On the other hand, ‘intermediate’ 
monocytes are known to more easily infiltrate the arterial wall compared with ‘classical’ 
CD14highCD16- cells thus suggesting a detrimental effect 31. However, in order to test the pro-
atherogenic relevance of ‘intermediate’ monocytes in human disease, interventional clinical 
trials would need to be conducted to establish whether therapeutic modulation of circulating 
monocyte profile impacts on plaque progression. To our knowledge, no such studies have been 
conducted to date.  
The biomolecular mechanisms underlying CD16 up-regulation on circulating monocytes have yet 
to be established. In the current study we found that induction of CD16 also occurs on PMNs 
post-immunisation in untreated participants, although the level of soluble CD16b, which is the 
isoform specifically produced by PMNs 19, decreased in the peripheral blood. This raises the 
possibility that expansion of the intermediate monocytic subset may be due to increased fixation 
of soluble CD16b (derived from PMNs) on the extracellular surface of circulating monocytes, 
rather than endogenous production of the CD16a isoform. Indeed, monocytes are known to 
absorb soluble CD16b on their extracellular membrane through engagement of CD11b/CD18 
and CD11c/CD18 molecules 233. Further work is required to characterise the mechanisms 
underlying CD16 upregulation in myeloid cells and to ascertain the functional consequences of 
this event in terms of monocyte biology. 
The present data are the first to show a therapeutic modulation of the phenotype of circulating 
monocytes induced by therapies conventionally used in primary and secondary prevention of 
cardiovascular disease, whose potential effect on plaque progression would therefore merit 
consideration in future clinical trials. In our study, all the tested anti-platelet regimes, namely 
the COX-inhibitor aspirin, used at high (300 mg) and low (75 mg) doses, and the P2Y12 antagonists 
clopidogrel and ticagrelor, were able to attenuate the expansion of ‘intermediate’ monocytes in 
the peripheral blood following immunisation. However, there appeared to be differences in 
efficacy between these treatments with respect to modulation of the phenotype of circulating 
monocytes that was found to be linearly correlated with their effectiveness in reducing soluble 
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P-selectin. We have previously shown that expression of P-selectin on activated platelets, and 
the consequent formation of MPA, is a key event in the acquisition of CD16 positivity by 
circulating monocytes 31. In this current study, I did not perform MPA measurement due to 
logistical limitations. While the monocytic phenotype remains stable in blood collected in EDTA 
tubes for up to 4 hours post-venepuncture 234, immediate blood processing is required for a 
reliable assessment of MPA in citrated plasma in order to avoid artefactual in vitro platelet 
activation 192. In this study, plasma separation could be performed soon after blood sampling, 
while the staining for flow cytometric assays was delayed by 30 min following venepuncture. 
Hence, soluble P-selectin was chosen as a platelet marker to provide a more reliable evaluation 
of platelet activity and an indirect measure of monocyte–platelet interaction, particularly in light 
of prior in vitro work conducted by our group that showed a significant rise in soluble P-selectin 
during MPA formation 31 and recent clinical evidence describing a significant contribution of P-
selectin to MPA formation in vivo 235.  
The different effects observed between treatments on the level of P-selectin, particularly 
between the two aspirin groups and the P2Y12 inhibitors, might be attributed to either a different 
pharmacological target, i.e. COX-inhibition vs. P2Y12 antagonism, or different pharmacokinetics. 
Indeed, aspirin achieves a dose-dependent maximum platelet inhibition within 2 hours post-
dose while clopidogrel requires 5 hours to reach a level of platelet inhibition of 60 % following a 
loading dose of 300 mg 86. These differences might have played a critical role particularly in a 
short-term study such as this. As regards to the two different aspirin groups, the slight apparent 
superiority of the 300 mg dose might be ascribed to dose-dependent inhibition of COX-activity 
with a consequent anti-inflammatory action greater than with low doses of aspirin (75 mg) 236. 
However, aspirin 300 mg did not modify the inflammatory biomarkers measured in this study, 
consistent with published evidence demonstrating a clinically relevant anti-inflammatory effect 
of aspirin only occurring at doses of 1 g or greater 237. 
In the large randomised-controlled PLATO trial, ticagrelor was found to be more effective than 
clopidogrel in reducing the incidence of cardiovascular events and all-cause mortality 122 238. 
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Although ticagrelor binds reversibly to the P2Y12 receptor and has a plasma half-life of only 
around 7 hours, it has previously been proven to be highly effective at inhibiting platelet 
activation 239. In our study, however, administration of ticagrelor did not achieve effective 
suppression of P-selectin, and indeed led to similar post-immunisation levels as in the untreated 
participants. The lack of efficacy of ticagrelor here may be related to the fact that we did not 
administer a loading dose (typically one dose of 180 mg, followed by maintenance 90 mg doses 
every 12 hours) in order to avoid further complicating the dosing regimen for this group, who 
already had a relatively high pill burden compared to the other groups. In retrospect, this may 
be responsible for the comparatively poor P-selectin inhibition observed in participants within 
this group, as it is likely that the 90 mg ticagrelor dose resulted in a slower onset of action and 
reduced inhibition of platelet activation stimulated by ADP compared with the loading 300 mg 
dose of clopidogrel.  
Overall, this evidence points towards platelet activity as the main determinant of monocyte  
phenotype shift in these results; this is particularly supported by the direct relationship found 
between amplitude of P-selectin reduction and change in monocyte phenotype in response to 
anti-platelet therapy. Similarity between the two groups of aspirin appears of particular 
relevance in light of the fact that aspirin 75 mg daily is the dose currently recommended for 
cardiovascular prevention, and no superior antithrombotic efficacy has been reported for aspirin 
300 mg daily 240-245.  
The lack of activity of anti-platelet therapy on the non-specific marker of inflammation, hs-CRP, 
suggests a targeted immunomodulatory action. Regarding production of pro-inflammatory 
cytokines, the phenotype of circulating monocytes did not influence the levels of TNFα, IL-1β, 
and IL-6 in our study participants, at least when measured 48 hours post-immunisation. There 
were no significant differences between their baseline and post-immunisation values in any of 
the groups. This is consistent with previously published reports showing an increase in hs-CRP 
in healthy subjects 2 days post-influenza immunisation that can be partly ascribed to an early 
rise in IL-6, but not TNF-α, 1 day post-immunisation 246 247. We cannot therefore exclude a change 
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in levels of inflammatory cytokines among groups at time points other than those analysed in 
the current study, particularly as a rise in IL-6 would be expected to precede the hs-CRP 
elevation. Due to logistical difficulties that resulted in a delay of up to 3 hours between taking 
blood samples and obtaining serum from these, levels of cytokines, and indeed P-selectin,  may 
have been affected. Also, the effect of treatment on monocyte distribution was not analysed 




I have demonstrated in this proof-of-concept study that anti-platelet therapy can attenuate the 
development of a CD16+ profile by circulating monocytes under pro-inflammatory conditions. 
Modulation of P-selectin levels seems to be a principal factor in determining the extent of this 
pharmacological action on monocytes, possibly linked to an interference in MPA formation; 
however, this remains to be confirmed. Further work is needed to better understand the 
underlying biomolecular mechanisms. A limitation of this study was the lack of inclusion of 
additional platelet biomarkers and functional assays, since these may have highlighted 
modulatory actions of anti-platelet drugs on specific platelet-dependent pathways. Further 
research is also needed to clarify whether the effects observed here with anti-platelet therapy 





























Netrins are a class of laminin-like proteins, which were initially isolated within the central 
nervous system and identified as regulators of embryonic axonal guidance. Netrin-1, by far the 
best-characterised member of the group, has subsequently been found to have a wide spectrum 
of regulatory roles in numerous pathological conditions, given its broad expression in 
inflammatory, vascular and tumour cell types and ability to control their survival, apoptosis and 
migration.  Netrin-1 has become particularly relevant within the field of oncology, where it has 
been shown to be of both diagnostic and prognostic value in many cancer subtypes 248 249, and 
there is much interest in the development of therapeutic antibodies that interfere with netrin-
1-dependent pathways as a potential novel chemotherapeutic approach 250. Netrin-1 is  also 
emerging as a therapeutic target in cardiovascular disease 222, having been shown in pre-clinical 
studies to modulate atherogenesis via the control of arterial inflammation 209, as well as exerting 
cardio- and renoprotective actions 251 252, and in this context, enhancing netrin-1 signalling may 
be desirable. 
To date, there has been limited characterisation of the in vivo pathways that regulate netrin-1 
expression in humans, limiting the development of targeted therapeutic strategies to achieve 
either a stimulatory or an inhibitory effect on the synthesis of this important molecule in the 
clinical setting.  
In vitro experiments in tumour cells have demonstrated that netrin-1 transcription is controlled 
by the NF-B and that NF-B-induced netrin-1 overexpression enhances cell survival 221. 
Subsequently, the existence of two distinct isoforms of netrin-1 has been reported, namely a 
nuclear truncated protein that promotes cell survival and a full-length isoform that undergoes 
secretion and induces proliferation 213.  
Previous work on the vascular endothelium by our group has shown that NF-B activation solely 
enhances expression of the nuclear isoform of netrin-1. On the contrary, pro-atherogenic 
vascular damage reduces the secretion of the endothelial-derived full-length isoform of netrin-
1 that protects against arterial inflammation by repelling myeloid cells and their plaque 
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infiltration 203. Administration of aspirin in a murine model of atherosclerosis counteracted the 
downregulation of secreted netrin-1 leading to a beneficial action in terms of plaque lipid 
content reduction. These experimental findings preceded the recently published clinical 
evidence showing reduced plasma levels of netrin-1 in patients with type 2 diabetes mellitus, 
thus suggesting that systemic pro-atherogenic inflammation downregulates circulating netrin-1 
in patients with cardiovascular disease, possibly via a detrimental effect on the vascular 
endothelium 253.  
In the current study, I investigated the effect of systemic inflammation on the circulating level 
of netrin-1 in relation to vascular function, and explored the therapeutic potential of aspirin in 
modulating netrin-1 in vivo in healthy subjects.  
 
3.2 Hypothesis and aim 
It has previously been demonstrated in animal models that aspirin preserves the synthesis of 
endothelial-derived netrin-1 under pro-inflammatory / pro-atherogenic conditions, thus 
reducing arterial inflammation. I explored the effect of aspirin on circulating netrin-1 levels in 
healthy volunteers and in the presence of endothelial dysfunction to test the hypothesis that 
anti-platelet therapy modulates netrin-1 levels in the presence of systemic inflammation. 
 
3.3 Methods 
3.3.1 Participant recruitment 
This was a post hoc study conducted on samples from 76 healthy volunteers previously recruited 
at Guy’s and St Thomas’ NHS Foundation Trust who underwent two separate clinical studies, 
and for whom serum samples were still available. All participants were aged 18 years or older 
(median: 31 years; IQR 25 - 38), had no significant past medical history, were not taking regular 
medications (aside from the combined oral contraceptive pill), and had not taken anti-platelet 
or anti-inflammatory drugs in addition to the study medications described below. 
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Cohort One comprised 36 participants from the clinical study described in Chapter Two of this 
thesis, wherein influenza immunisation was used as an experimental model of mild 
inflammation to evaluate the effect of different anti-platelet regimes on a number of 
inflammatory biomarkers, including cytokines, monocyte phenotype, and hs-CRP 18. Serum 
samples were collected before and 48 hours after receiving the seasonal influenza vaccine, and 
in the presence of one of the following treatment regimens:  
 
Group 1 aspirin 300 mg once daily (n = 9) 
Group 2: aspirin 75 mg once daily (n = 9) 
Group 3: clopidogrel with an initial loading dose of 300 mg followed by a further dose of 75 mg 
24 hours later (n = 9) 
Group 4: untreated participants (n = 9; serving as controls) 
 
We did not include data from participants who had been treated with ticagrelor in the original 
study, due to relatively poor platelet inhibition with this anti-platelet agent, which was 
demonstrated by an inability to suppress P-selectin levels in response to inflammation (see 
Chapter Two).  
Cohort Two comprised a separate group of 40 healthy volunteers. Participants were previously 
recruited into a clinical study which set out to identify novel biomarkers of aspirin resistance 
following 28 days of treatment with aspirin 300 mg once daily 254. Table 3.1 shows the pooled 
baseline characteristics of all participants from Cohorts One and Two. 
The clinical studies into which the participants were recruited had been reviewed and given 
favourable opinion by the NRES London—Dulwich Research Ethics Committee (ref. number 
13/LO/1664; South London network study identification number 16644) and the Riverside 
Research Ethics Committee, London, UK (ref. number 07/Q0401/1) and registered on the UK 
Clinical Research Network Portfolio. All participants gave informed consent. The studies were 
performed conforming to the Declaration of Helsinki. 
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3.3.2 Collection of serum 
For Cohort One participants, 12 ml serum was collected using methods described in Chapter 
Two. For Cohort Two participants, 7 ml whole blood was collected into a tube containing a serum 
gel separator and 10 μg/ml indomethacin was added to the tubes to inhibit further activity of 
the COX enzymes. The whole blood collection and preparation for Cohort Two subjects was 
performed by Dr Timothy Goodman, whilst I collected and prepared all whole blood samples for 
Cohort One.  
 
3.3.3 Enzyme-linked immunosorbent assays 
ELISAs were carried out to measure serum and urine levels of netrin-1 using commercially 
available kits (SEB827Hu, Cloud-Clone Corp.), as per manufacturer instructions (inter-assay 
variability was found to be <5 %).  
Briefly, 100 μl netrin-1 standards (0 - 2000 pg/ml) and neat serum or urine samples were added 
in duplicate to a 96-multi-well plate pre-coated with an antibody specific to netrin-1. Following 
incubation for 2 hours at 37 ºC, 100 μl biotin-conjugated polyclonal antibody specific for netrin-
1 was added to each well and the plate was incubated for 1 hour at 37 ºC. The plates were 
washed and subsequently incubated with 100 μl avidin conjugated to horseradish peroxidase 
for 30 minutes. The plates were washed again and 90 μl TMB substrate was added to the wells. 
After 10 minutes, 50 μl 0.16 M sulphuric acid was added to the wells to stop further colour 
change. The plates were analysed using a microplate optical density reader at 450 nm 
wavelength. A standard curve was constructed by plotting the optical densities of the standards 
against the corresponding known netrin-1 concentrations. Serum netrin-1 concentrations in the 
different samples were read from the standard curve on the basis of their optical density 
readings; Figure 3.1. 
ELISA kits were also used to measure serum levels of PGE2 (ID: MBS007171, MyBioSource, Inc., 
USA), TXB2 (ID: CSB-E08046h, Cusabio, China), pepsinogen I (ID: CSB-E17538h; Cusabio, China), 
renin (ID: E-EL-H0119, Elabscience), VCAM-1 (ID: DVC00, R&D Systems, UK), ICAM-1 (ID: 
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850.540.096, Diaclone, France), myeloperoxidase (MPO; ID: BMS2038INST; eBioscience, 
Austria), and E-selectin (ID: CSB-E04540h, Cusabio, China), in addition to urinary levels of 
cysteinyl leukotriene (ID: 10009291; Cayman Chemical Company, USA) using a similar technique 
to that stated above, with variations based on manufacturer instructions. Urinary TXB2 levels 
were measured for Cohort 2 participants by Dr Tim Goodman, using a commercially available kit 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.1: A representative standard curve from the netrin-1 enzyme-linked immunosorbent 
assay 
The optical density reading (at 450 nm) was plotted against the netrin-1 concentration to obtain a 





3.3.4 Serum biochemistry 
Methods for measuring serum renal profiles and lipid levels were described in Chapter Two of 
this thesis. Hs-CRP was measured by Quintiles Drug Research Unit laboratories, London. 
 
3.3.5 Measurement of serum salicylate levels 
Serum salicylate levels were measured by Dr Timothy Goodman and Professor Anthony 
Wierzbicki using a Roche Cobas Fara automated analyser at St Thomas’ Hospital, London. 5 μl of 
calibrator, control, blank (double-distilled water) or sample was added to a cuvette. Next 75 μl 













































nicotinamide adenine dinucleotide reagent was added to each sample or blank. The reaction 
was then activated through the addition of 150 μl salicylate hydroxylase and the absorbance at 
340 nm of each reaction mixture was measured. 
 
3.3.6 Calculation of creatinine clearance 
The Cockcroft-Gault equation, ((140 – age in years) x (weight in kg) x (0.85 if female)) / (72 x 
creatinine in µmol/l) was used to calculate creatinine clearance. 
 
3.3.7 Western blotting 
Western blotting of serum samples was performed with both rat anti-netrin-1 and goat anti-
netrin-1 primary antibodies as previously described 203. Prior to use, serum was treated, as per 
previously reported methodology 255, for lipid, IgG and albumin depletion. Briefly, samples were 
centrifuged for 15 minutes at 15000 x g at room temperature to remove the lipid component; 
IgG depletion was subsequently performed on the delipidated serum with a Protein G Sepharose 
bead suspension (10278424, GE Healthcare Ltd, UK), and was followed by centrifugation in cold 
ethanol to remove the albumin-rich serum fraction 255.  
Proteins were subsequently re-suspended in radioimmunoprecipitation assay buffer and their 
concentration measured by bicinchoninic acid assay; section 3.3.8. 10 mcg of each protein 
sample was separated on a SDS-PAGE gel (10 % acrylamide), and transferred to a polyvinylidene 
difluoride membrane. After 1 hour blocking in phosphate buffer saline containing 5 % milk / 0.1 
% Tween-20, the membranes were probed with either rat anti-netrin-1 or goat anti-netrin-1 
antibodies (both 1:100 in blocking solution; R&D System), for 2 hours at room temperature. After 
washing, membranes were incubated with goat anti-rat or donkey anti-goat secondary 
antibodies as appropriate (1:2000; Cell Signalling, UK). Bands were detected with enhanced 





3.3.8 Bicinchoninic acid protein assay 
BSA standards were prepared from 2 mg/ml solution (ID: 500-0206, Bio-Rad) as follows: 
 
BSA mg/ml 0.0 0.1 0.3 0.6 0.9 1.2 1.5 1.8 2.0 
Volume of 2 mg/ml stock (µl) 0 25 75 150 225 300 375 450 400 
Volume of RIPA buffer 500 475 425 350 275 200 125 50 0 
 
10 µl of either standards or serum samples were added to each well of a 96-well plate. 
Bicinchoninic acid working solution was prepared by combining Reagent A (sodium carbonate, 
sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide) and 
Reagent B (4 % cupric sulphate) in a 50:1 ratio (reagents from Thermo Scientific), and 200 µl of 
this was pipetted into each well. The plate was incubated for 30 minutes at 37 ºC and then 
analysed using a microplate optical density reader at 490 nm wavelength. A standard curve was 
constructed and the protein concentrations from the serum samples were calculated using this.  
 
3.3.9 Whole blood flow cytometry 
Whole blood was immunostained using the technique described in Chapter 2, with a peridinin-
chlorophyll-protein complex-cyanine 5 (PerCP-Cy5) goat anti-rat netrin 1 antibody (2BScientific, 
UK), in addition to the aforementioned PE-mouse anti-human CD14 and FITC-conjugated anti-
human CD16 antibodies.  
The samples were analysed using a BD FACSCalibur (BD Bioscience) flow cytometer to determine 
monocyte subset distribution. A total of 100,000 events were acquired and post-acquisition 
analysis was performed using FlowJo (version 10) software. Monocytes were identified on an 
FSC versus SSC plot and gated to distinguish the different subsets of monocytes based on CD14 
and CD16 surface expression, and to identify whether netrin-1 was expressed on the monocytic 




3.3.10 Measurement of netrin-1 levels in vitro 
Human umbilical vein endothelial cells (HUVEC) were isolated by Dr Virginia Tajadura-Ortega 
from umbilical cords donated by healthy mothers following uncomplicated deliveries using 
previously described methods 256. HUVEC were incubated with PGE2 (ID: 14010; Caymen 
Chemical Company, USA) re-suspended in dimethyl sulfoxide  (DMSO) at concentrations of 10 
nm and 100 nm for 4 hours and for 24 hours by Dr Virginia Tajadura-Ortega. HUVEC incubated 
with equivalent volumes of DMSO were used as control experiments. I subsequently measured 
netrin-1 levels in the cell supernatant from these experiments using an ELISA kit, as described in 
Section 3.3.3. 
 
3.3.11 Statistical analysis 
Statistical analyses were performed using GraphPad Prism (version 6.0) software. Parametric 
data are expressed as the mean ± SEM, whilst non-parametric data are expressed as the median 
with IQR. ANOVA was used to compare percentage variation of each study variable between the 
4 treatment groups in the influenza immunisation study. Baseline and post-treatment values 
were compared within each group using a paired parametric or non-parametric test as 
appropriate. Netrin-1 correlation with the other study variables was analysed by Spearman 




3.4.1 Circulating levels of netrin-1 are reduced in the presence of endothelial dysfunction 
Influenza immunisation was previously reported to induce vascular dysfunction in healthy 
volunteers 27 32. In accordance with these data, our study showed an increase in the serum level 
of VCAM-1, which rose from a baseline level of 493.70 ± 44.34 ng/ml to 542.30 ± 49.60 ng/ml 
post-immunisation in participants not treated with anti-platelet medication (Group 4; p = 0.0022 
vs baseline); Figure 3.2. Levels of PGE2, which is known to have a protective effect on the vascular 
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endothelium under steady state conditions 257-260, fell from 320.90 ± 55.04 pg/ml to 189.50 ± 
30.37 pg/ml in the same group of participants (p = 0.0199 vs baseline); Figures 3.3 – 3.4. 
Similarly, there was a significant reduction of 29.25 % in the circulating level of netrin-1, from 
311.90 (IQR 248.00 – 316.30) pg/ml to 220.20 (IQR 202.20 – 287.70) pg/ml at baseline and post-
immunisation respectively, p = 0.0017; Figures 3.3 – 3.4.  
All anti-platelet treatment regimens suppressed this rise in VCAM-1, with the highest degree of 
suppression observed in those taking the daily 300 mg dose of aspirin, although there were no 
statistically significant differences in efficacy between the treatment groups (Figure 3.2). The 
reduction in PGE2 levels post-immunisation was attenuated by aspirin treatment, whilst in the 
clopidogrel-treated group a tendency towards an increase in PGE2 was observed. The changes 
in netrin-1 in response to immunisation followed the same pattern as the PGE2 changes in all 
three treatment arms. An increase in the level of netrin-1 reaching statistical significance was 
observed in the clopidogrel group (20.96 % change from baseline; p = 0.0033 vs untreated), 
whilst aspirin counteracted the suppression of netrin-1 post-immunisation in what appeared to 
be a dose-dependent manner (% change from baseline in Group 1 and Group 2 were -3.06 and 
-17.03 respectively; p = 0.0465 and p>0.05 vs untreated; Figure 3.3)  
Levels of TXB2, a marker of platelet activation and aggregation, fell significantly from 3416.0 ± 
285.7 ng/ml at baseline to 3130.0 ± 244.0 ng/ml post-immunisation in the group receiving 
aspirin 300 mg daily (p = 0.0296). There was an apparent reduction in TXB2 also in those 
participants on aspirin 75 mg daily, however this did not reach statistical significance (p = 
0.2103). Post-immunisation TXB2 levels remained stable in the participants not treated with anti-
platelet agents and in those taking clopidogrel; Figure 3.5. Of note, these TXB2 measurements 
were higher than previously reported TXB2 levels in healthy volunteers (16785341, 22098110), 
















Figure 3.2: Percentage change in vascular cell adhesion protein 1-1 post-immunisation 































Figure 3.3: Percentage change in prostaglandin E2 and netrin-1 post-immunisation 
Panels A and B show the percentage change in PGE2 and netrin-1 levels respectively across groups. P 























Figure 3.4: Prostaglandin E2 and netrin-1 absolute values pre- and post-immunisation 








































































































































































Figure 3.5: Percentage change in thromboxane B2 post-immunisation 




3.4.2 Netrin-1 levels are directly related to prostaglandin E2 production 
In a multiple regression analysis of the correlation between netrin-1 levels and all other study 
parameters, including TXB2 and PGE2, as well as the previously measured hs-CRP, cytokines, P-
selectin levels and monocyte cell subset count, I found that changes in netrin-1 levels in response 
to immunisation were linearly and directly related with changes in PGE2 concentration only 
(r=0.6103; p=0.0002; Figure 3.6). No additional significant findings emerged.  
In order to further delineate the regulatory relationship between PGE2 and netrin-1 synthesis, I 
measured netrin-1 levels in Cohort Two – healthy volunteers following once daily treatment with 
300 mg aspirin, which is known to exert an inhibitory action on both COX isoforms when used 
at this dose, for 28 days.  Drug treatment in this cohort, as expected, led to a significant reduction 
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in both TXB2 and PGE2 levels (Figure 3.7). This latter fell from 331.9 ± 69.04 pg/ml at baseline to 
89.99 ±34.29 pg/ml post-aspirin therapy (p = 0.0114).  
There was a mild but consistent reduction in serum netrin-1 from a baseline level of 303.9 (IQR: 
218.4 – 386.0) pg/ml to 246.9 (IQR: 193.2 – 316.2) pg/ml post-aspirin therapy in all study 
participants (p = 0.0012), Fig 3.8. When combining baseline and post-treatment values of all 
study variables, a strong positive correlation was found between netrin-1 and PGE2 levels (r = 
0.3584; p = 0.0015) only; Figure 3.9. The percentage change in netrin-1 was found to be 
negatively correlated with serum salicylate levels (r = -0.5370; p = 0.0100), indicating that the 
reduction in netrin-1 was causally related to aspirin therapy; Figure 3.10. Of note, there was a 
wide variation in salicylate levels between participants, likely representing poor adherence with 















Figure 3.6: Correlation between percentage change in prostaglandin E2 and netrin-1 levels 
post-immunisation 



























Figure 3.7: Thromboxane B2 and prostaglandin E2 levels pre- and post-aspirin  
Graphs showing the reduction in both TXB2 (A) and PGE2 (B) following 28 days of treatment with aspirin 





















Figure 3.8: Serum netrin-1 levels pre- and post-aspirin 













Figure 3.9: Correlation between netrin-1 and prostaglandin E2 levels 














Figure 3.10: Correlation between percentage change in netrin-1 levels post-immunisation and 
serum salicylate levels 
The reduction in netrin-1 was associated with increased serum salicylate levels. 
 
 
3.4.3 Aspirin-induced inflammatory changes are not responsible for the observed reduction in 
netrin-1 levels  
Serum VCAM-1 remained unchanged from baseline levels of 527.32 ± 15.46 ng/ml to 519.10 ± 
15.76 ng/ml post-aspirin. ICAM-1 and E-selectin were also unmodified, indicating that there was 
no change in the inflammatory status of the endothelium in response to aspirin administration; 
Figure 3.8. Levels of hs-CRP were also not modified; Figure 3.11.  
Leukotrienes are members of the eicosanoid family that are produced at the sites of 
inflammation by numerous cells, including monocytes, as a result of AA metabolism 261. We 
measured urinary cysteinyl leukotriene levels in Cohort Two participants, as a mediator of the 
inflammatory response. Levels were unchanged post-aspirin treatment (baseline 1081.0 ± 110.1 
pg/ml to 984.1 ± 76.35 pg/ml post-aspirin; p = 0.3645), again confirming the lack of inflammatory 
response to aspirin therapy in these healthy subjects; Figure 3.12.  
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In view of the role that netrin-1 plays in monocyte trafficking and the pathophysiology of 
atherosclerosis, I measured MPO levels in Cohort Two participants pre- and post-aspirin therapy. 
MPO is a peroxidase enzyme that is found in the azurophilic granules of neutrophils and the 
lysosomes of monocytes, and plays a key role in their microbicidal activity. The enzyme may 
additionally mediate atherogenesis, via the oxidation of lipoproteins, and has been suggested 
to potentially represent a biomarker of coronary artery disease 262, as well as inflammation. I 
identified no statistically significant change in MPO levels after 28 days of aspirin therapy 
(baseline 1739 (IQR: 1099 – 2715) pg/ml to 870 (IQR: 530 – 2910) pg/ml post-treatment; p = 
0.4105); Figure 3.13.  
Lastly, as long term use of non-steroidal anti-inflammatory drugs, including aspirin, reduces 
prostaglandin synthesis, which is a key component in gastric mucosal defence, I wished to 
reasonably exclude gastric inflammation as a potential cause for the fall in netrin-1. I measured 
serum pepsinogen I levels, as a marker of gastritis that has been shown to rise following NSAID-
induced gastritis 263 and found no significant change from pre- to post-aspirin (baseline 302.5 



























Figure 3.11: Change in markers of endothelial dysfunction and inflammation 
There was no change in markers of endothelial dysfunction, VCAM-1 (A), ICAM-(B), or E-selectin (C). Hs-























Figure 3.12: Cysteinyl leukotriene levels pre- and post-aspirin  











Figure 3.13: Myeloperoxidase levels pre- and post-aspirin  











Figure 3.14: Pepsinogen I levels pre- and post-aspirin  
There was no significant change in pepsinogen I levels following 28 days of aspirin 300 mg once daily. 
 
 
3.4.4 The reduction in netrin-1 is not related to renal function 
In view of numerous reports of circulating netrin-1 levels falling in response to renal impairment 
214 264-266, in addition to a previous study showing that long-term use of 300 mg aspirin daily leads 
to a reduction in creatinine clearance in healthy young adults 267, I assessed for potential changes 
in renal function from pre- to post-aspirin treatment in Cohort Two participants that may have 
contributed to the observed reduction in serum netrin-1 levels.  
There were no significant changes in creatinine levels (baseline 73.22 ± 1.36 µmol/l to 72.88 ± 
1.40 µmol/l post aspirin), creatinine clearance (baseline 114.10 ± 3.26 ml/min to 113.69 ± 3.47 
ml/min), or estimated glomerular filtration rate (baseline 95.57 (IQR: 86.80 – 107.00) 
ml/min/1.73 m2 to 96.16 (IQR: 85.54 – 110.00) ml/min/1.73 m2). There was also no correlation 
between netrin-1 levels and any of these measures of renal function. 
Murine ischaemia-reperfusion injury models have shown that down-regulation of circulating 
netrin-1 occurs concomitantly with its up-regulation in tubular cells, leading to increased urinary 
netrin-1 secretion 219 268 and urinary netrin-1 levels are known to be directly correlated with renal 
function and indeed function as a biomarker for renal injury in humans 264. I measured netrin-1 
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levels in the urine of Cohort Two participants and initially identified a reduction in urinary netrin-
1 levels post-aspirin therapy. When these values were normalised for urinary creatinine, 
however, there was no significant change; Graph 3.12. There was also no correlation between 










Figure 3.15: Urinary netrin-1 levels pre- and post-aspirin (normalised for urinary creatinine) 
There were no significant changes in urinary netrin-1 levels post-aspirin treatment. Baseline levels were 












3.4.5 Aspirin administration causes a reduction in serum renin levels 
It has previously been shown that plasma renin concentrations fall upon treatment with aspirin, 
albeit at higher doses than those used in our study 269. A reduction in plasma renin levels has 
also been observed in response to nocturnal administration of low dose (100 mg) aspirin 270. I 
measured serum renin levels in the Cohort Two participants and identified a significant 
reduction post-aspirin treatment. Renin levels fell by 26.97 % from a baseline level of 339.7 (IQR: 










Figure 3.16: Renin levels pre- and post-aspirin 
Graph showing the significant reduction in serum renin levels following 28 days of treatment with 








3.4.6 Western blotting of serum netrin-1 isolated the truncated isoform only 
To characterise the netrin-1 isoform that was being measured in serum samples by ELISA, I 
performed Western blotting using a rat anti-netrin-1 antibody to specifically target the full 
length, 70 kDa protein, and a goat anti-netrin-1 antibody against the truncated, 55 kDa protein. 
Initially, I was unable to detect any antibody signal (Figure 3.13), however once I treated the 
serum to remove lipids, IgG, and albumin, the netrin- 1 protein was detected. I was only able to 
detect the truncated isoform of netrin-1 in serum samples with either antibody (Figure 3.13).  
 
3.4.7 Netrin-1 was not identified on the cell surface of monocytes 
Flow cytometry was performed to identify cell surface markers, including CD14, CD16, and 
netrin-1. There was no antibody signal from the PerCP-Cy5 goat anti-rat netrin 1 antibody, 



























Figure 3.17: Western blotting of serum for netrin-1 
I performed Western blotting of serum to measure netrin-1 levels. Prior to treating the serum to remove 
lipids, IgG, and albumin, the results were uninterpretable (A). Once the serum had been treated to 











3.4.8 Netrin-1 levels are not modified following exposure of endothelial cells to prostaglandin 
E2 in vitro 
In view of the observed correlation between changes in netrin-1 and PGE2, netrin-1 was 
measured in cell supernatant from HUVEC at baseline and following either 4 or 24 hours of 
incubation with PGE2 at 10 nM and 100 nM concentrations or DMSO. There was no detectable 
change from baseline in netin-1 levels following exposure to PGE2 or DMSO at either time point. 
Further concentrations of PGE2 were not tested, as higher concentrations have been shown to 
stimulate cell proliferation, which would thus render the data uninterpretable 271.  
 
3.5 Discussion 
Prior in vitro work and animal experimentation have demonstrated that a dysfunctional 
endothelium markedly loses its ability to secrete netrin-1, and this compromises the integrity of 
the vascular barrier against inflammatory cell infiltration 203. The current clinical study partly 
confirms these experimental data, whilst offering insight into the biomolecular mechanisms that 
regulate the synthesis of serum netrin-1 in humans. 
Endothelial dysfunction, which is a systemic perturbation of vascular homeostasis characterised 
by impaired endothelium-dependent vasodilation and an associated state of endothelial 
activation, is not only  triggered by pathological stimuli such as cardiovascular risk factors or 
immunological disorders but also occurs as part of physiological host defence mechanisms 272 
273, such as occurs in the context of inflammation. The evidence provided by other authors 
demonstrating endothelial activation induced by influenza immunisation, were confirmed by 
the increased level of VCAM-1 observed in our participants 48 hours post-immunisation, thus 
supporting the validity of the influenza immunisation as an experimental model to study the 
relationship between endothelial dysfunction and circulating levels of netrin-1 in humans. In 
accordance with prior research performed in several animal models of inflammation, I found 
that endothelial activation, as driven by inflammatory stimuli, is also paralleled by a reduction 
in the serum concentration of netrin-1 in healthy subjects. This effect was abolished by all anti-
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platelet treatments and was independent of their ability to inhibit platelet activation or to 
suppress systemic inflammation. Indeed, I have shown the lack of efficacy of both aspirin and 
clopidogrel in modulating the rise in hs-CRP with this experimental model of inflammation in 
data presented in Chapter Two. Moreover, whilst aspirin 300 mg exerted the strongest inhibition 
on platelet activity, as evidenced by a more effective suppression of P-selectin and TXB2 in 
response to vaccination compared to clopidogrel, this latter was better at restoring netrin-1 
synthesis in the peripheral blood of our immunised participants. The protective action of all anti-
platelet agents on the vascular endothelium was similar, as demonstrated by their comparable 
effects in terms of suppression of the rise in VCAM-1 induced by immunisation. Aspirin alone, 
however, induced COX inhibition and this was found to account for the changes in the 
production of netrin-1 in both the immunisation study and the 28-day aspirin 300 mg 
interventional study.  
These data demonstrate that netrin-1 reduction, as occurs in the presence of a dysfunctional 
endothelium caused by immunisation, occurs in parallel with PGE2 reduction. In the absence of 
endothelial dysfunction, pharmacological inhibition of the COX enzymes, resulting in reduced 
PGE2 production, also induced a small but significant decrease in netrin-1 levels. The TXA2 
pathway does not appear to be involved in netrin-1 regulation, as modulation of netrin-1, both 
in subjects receiving influenza immunisation and in those receiving high-dose aspirin for 28 days, 
was not related to changes in serum TXB2. Although I measured PGE2 here, I cannot exclude the 
possibility that additional COX-dependent endothelium-derived prostanoids, such as PGI2, that 
generally follow the same expression pattern in healthy endothelium 274, would show a similar 
association with netrin-1 under these experimental conditions. However, considering the prior 
demonstrated modulatory effect of netrin-1 on COX-2 expression and PGE2 synthesis, it is 
intriguing to note that there is a regulatory link between COX-activity, COX-dependent 
prostaglandin production, and netrin-1 that may have important functional and therapeutic 
implications. Numerous studies have demonstrated that PGE2 is protective against endotoxin 
injury, and promotes endothelial barrier enhancement 257-260 275 276 as well as cell survival 277 278. 
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PGE2 additionally has somewhat contradictory roles as both a direct mediator of early-stage 
inflammation and a suppressor of non-specific inflammation via modulation of IL-10 and pro-
inflammatory cytokines 279. The observed reduction in PGE2 in response to immunisation was 
abolished by all anti-platelet therapy regimes, likely due to their beneficial effect on the vascular 
endothelium that, in turn, preserved its ability to synthesise protective vasoactive molecules 
and / or reduced PGE2 consumption. 
Local levels of PGE2 derive from both its synthesis and degradation rates. Of note, there was a 
tendency towards an increase in PGE2 levels in those taking clopidogrel, which may be related 
to the suppression of endothelial activation driven by the anti-platelet drug, without the 
additional effect of COX inhibition and subsequent reduced prostanoid production, which occurs 
with aspirin therapy.  
The anti-inflammatory action exerted by anti-platelet agents on the vasculature that emerged 
in this study could partly be ascribed to their ability to suppress expansion of the pro-
inflammatory monocytes that we have previously demonstrated in this human model of 
inflammation 18. Several elements of discordancy were noted in this clinical study compared to 
previous research from our group in animal models of atherosclerosis treated with the same 
anti-platelet agents 203.  The superior effect of aspirin over clopidogrel in counteracting netrin-1 
reduction in atherosclerotic mice was not confirmed in this clinical study; rather, clopidogrel 
demonstrated a better ability to maintain circulating levels of netrin-1 under pro-inflammatory 
conditions in humans. This discrepancy may be attributable to the distinct modulation of the 
tested anti-platelet agents on PGE2 production, which has emerged as a potential factor 
implicated in the regulation of netrin-1 in human physiological settings.  
Moreover, we were only able to detect the truncated isoform of netrin-1 in the peripheral blood 
of our healthy subjects, whilst previous in vitro experiments on endothelial cells reported a 
specific action of aspirin exerted on the full-length secreted isoform of the protein through an 
epigenetic modification of chromatin. The possibility that lack of expression of full-length netrin-
1 is due to the phenomenon of protein truncation occurring in human serum cannot be 
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excluded. Furthermore, one of the limitations of the immunisation arm of this study was that 
serum samples were only available from two time-points, 48 hours apart, and we therefore have 
not established whether similar trends in netrin-1 and PGE2 levels would have been present in 
an earlier stage of the inflammatory response and how the relationship between the two 
markers would have progressed until resolution of inflammation. 
Further analysis of our group’s previously published in vitro data from human endothelial cells 
in fact revealed that stimulation of cells with aspirin alone (in the absence of TNF as a co-
stimulatory agent) showed a tendency, albeit not statistically significant, towards a reduction in 
netrin-1 release into serum supernatants compared to non-aspirin-treated cells. In light of the 
new data that have emerged from the current clinical study, it is possible that the aspirin-
induced PGE2 reduction, which was reported in the prior in vitro set of experiments, may have 
accounted for a subtle difference in netrin-1 that only became evident and statistically relevant 
in the in vivo human study here described. Furthermore, the cellular sources of both circulating 
netrin-1 and PGE2 measured in our clinical study, remain to be established. Our primary focus 
was on the vascular endothelium, whose function was assessed by measuring classical 
endothelial-derived adhesion molecules. However, the lack of a direct relationship between 
either netrin-1 or PGE2 and endothelial markers or monocyte subtype cell count implies a 
multicellular source for both molecules. Hence, PGE2 and netrin-1 may also be derived from cell 
types other than endothelial cells, such as inflammatory cells, and these could have contributed 
to the modulation of systemic inflammation and/or activation of the vascular endothelium.  
Interestingly, I observed a reduction in serum renin levels in response to aspirin treatment in 
the Cohort Two participants, who were treated with 28 days of aspirin 300 mg once daily, 
without any apparent effect of the drug on renal function. Renin is produced by the 
juxtaglomerular cells in the kidney, and is secreted as a homeostatic response to reduced arterial 
blood pressure. It has been suggested that aspirin treatment could lead to reduced renin 
secretion due to inhibition of prostaglandin-induced vasodilation, thus resulting in a higher 
baseline blood pressure 267 270. It appears that, in this instance, prostaglandin inhibition by aspirin 
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may have resulted in a subclinical change in vascular tone and renal perfusion, thus reducing 
renin secretion. We also sought to establish whether the observed netrin-1 reduction in Cohort 
Two was related to a change in the status of endothelial activation induced by aspirin treatment. 
Netrin-1 is expressed abundantly throughout the endothelium where it is downregulated by pro-
inflammatory cytokines and shear stress. The same stimuli induce ICAM-1 and E-selectin 
upregulation in endothelial cells 218 220. We found no change in markers of endothelial activation 
or systemic inflammation (as measured by hs-CRP), nor in specific pathways that were linked to 
COX inhibition and netrin-1 suppression, thus effectively excluding netrin-1 reduction being 
explained by a change in inflammatory status. 
PGE2 possesses important immunomodulatory properties that are concentration-related, and 
its levels are regulated by both synthesis, mainly sustained by COX-2 activity, and degradation 
rates 279. Hence, whilst PGE2 upregulation, as driven by NF-κB inducers in the context of an acute 
inflammatory response, has detrimental pro-inflammatory effects on the vasculature by 
enhancing endothelial permeability, a reduced bioavailability of PGE2 may also be damaging the 
endothelium by removing a pro-survival factor. In keeping with this, netrin-1 may represent the 
mediator of PGE2, particularly the truncated isoform that has been mainly related to cell survival, 
at least in cancer cells, further supporting the link between levels of PGE2 and truncated netrin-
1 that we have observed in this clinical study.  
This biomolecular interplay between COX inhibition and netrin-1 may have important 
therapeutic implications. Previous investigators have found that netrin-1 regulates COX-2 
expression within the kidney via NF-κB activation and thus directly modifies PGE2 production in 
a murine model of renal inflammation 221. The amplitude of PGE2 reduction in our immunised 
participants, both treated and untreated with anti-platelet agents, was strongly related to the 
extent of reduction in netrin-1. Similarly, the baseline and post-treatment levels of both markers 
in serum from healthy subjects who took aspirin 300 mg daily for 28 days were strongly 
correlated with one another, confirming the existence of a direct relationship between these 
two parameters. However, our data point towards a potential regulatory role exerted by PGE2 
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on netrin-1 synthesis. The 28-day treatment period with aspirin 300 mg daily primarily targeted 
prostaglandin production through COX-inhibition. The concomitant reduction in circulating 
netrin-1 levels, which occurred in the absence of any inflammatory stimulus (as confirmed by 
stable levels of hs-CRP) and endothelial dysfunction (as demonstrated by unmodified levels of 
endothelial markers), is likely to be secondary to this. The COX-dependent modulation of netrin-
1, with potential interactions with prostanoids, including PGE2, appears intriguing in 
consideration of the emerging role of netrin-1 as a cardiovascular target, as well as the recent 
evidence highlighting the pro-metastatic effect of PGE2 in adenocarcinoma cells 280, and the 
potential beneficial effect that was demonstrated with in vitro experiments using aspirin in this 
cancer subtype, for which netrin-1 overexpression was found to play important roles in terms 
of cell survival and proliferation as well as to have prognostic implications in clinical studies  
 
3.6 Conclusion 
Our data suggest that circulating netrin-1 levels appear to be directly modulated by changes in 
COX-dependent vasoactive molecules, such as PGE2. Given the emerging role of netrin-1 in 
cardiovascular disease and as an oncological target, we believe that further exploration of the 
pathways that control netrin-1 production and its relationship with clinical outcomes may be 






















THE ROLE OF CD16+ MONOCYTES IN OXIDISED  







Atherogenesis is strongly associated with chronic inflammatory states 8 and patients with 
elevated markers of inflammation have an increased risk of subsequent cardiovascular events 4 
5, indicating that dysregulation of immune function may be one of the key factors involved in 
plaque formation. OxLDL accumulates at sites of atherosclerosis, inducing an immunological 
response with generation of anti-oxLDL autoantibodies by B cells 281 282.  
HMG-CoA reductase inhibitors (statins), which act to reduce circulating LDL levels, are among 
the most commonly prescribed therapies for patients with cardiovascular risk factors 283 
although novel immunomodulatory drugs that reduce synthesis or increase clearance of LDL are 
currently in development 11 12. IgG and IgM autoantibodies against oxLDL have been assessed as 
potential biomarkers of coronary artery disease and whilst associations have been found, there 
is no definitive evidence that they represent independent predictors of atherogenesis or 
cardiovascular events 14 284 and the pathways linking oxLDL to plaque generation remain unclear. 
As shown in Chapter Two, anti-platelet agents are capable of modifying the phenotype of 
circulating monocytes, as denoted by their surface expression of CD14 and CD16 18. CD16 is a 
low affinity Fc γ receptor that is activated upon binding to IgG, thus initiating phagocytosis. 
Polymorphisms of Fc γ receptors for IgG may be associated with increased coronary 
atherosclerosis and it has been hypothesised that variations in these receptors may moderate 
the clearance of IgG antibodies by monocytes and macrophages and thus modify plaque 
formation 20. 
 
4.2 Hypothesis and aim 
Patients with cardiovascular disease are known to have increased levels of circulating 
CD14highCD16+ monocytes 22 23 but it has yet to be established whether this increase contributes 
directly to cardiovascular risk or is instead a protective mechanism that acts, for example, to 
modify oxLDL levels.  
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I evaluated the impact of CD16+ monocyte reduction on the circulating levels of oxLDL and IgG 
anti-oxLDL in the context of a non-atherogenic immunological reaction to test the hypothesis 
that CD16 plays a critical role in the transduction of signalling pathways triggered by oxLDL. 
 
4.3 Methods 
4.3.1 Participant recruitment 
This was a post hoc study conducted on samples obtained from 40 healthy volunteers previously 
recruited at Guy’s and St Thomas’ NHS Foundation Trust, who participated in the clinical study 
described in Chapter Two and for whom serum samples were still available. All participants were 
aged 18 years or older (median: 30.5 years; IQR 24.5 - 38), had no significant past medical 
history, were not taking regular medications (aside from the combined oral contraceptive pill), 
and had not taken anti-platelet or anti-inflammatory drugs in the preceding fortnight. 
Study volunteers received influenza immunisation, which is an established model of mild, 
systemic inflammation 30 and one of the 48 hour treatment regimens listed below. Serum 
samples were collected before and 48 hours after receiving the seasonal influenza 
immunisation, and in the presence of one of the following treatment regimens:  
 
Group 1 aspirin 300 mg once daily (n = 10) 
Group 2: aspirin 75 mg once daily (n = 10) 
Group 3: clopidogrel with an initial loading dose of 300 mg followed by a further dose of 75 mg 
24 hours later (n = 10) 
Group 4: untreated participants (n = 10; serving as controls) 
 
Once again, I did not include data from participants who had been treated with ticagrelor in the 
original study, due to relatively poor platelet inhibition with this anti-platelet agent, which was 
demonstrated by an inability to suppress P-selectin levels in response to inflammation (see 




4.3.2 Collection of serum 
Serum was collected at baseline and 48 hours later using methods described in Chapter Two. 
Serum was stored at -80 °C for 6-9 months until it was utilised for the experiments described 
below. 
 
4.3.3 Enzyme-linked immunosorbent assays 
ELISAs were performed using commercially available kits as per manufacturer instructions, to 
measure serum levels of oxLDL (ID: STA-369; Cell Biolabs, Inc., USA), MPO (ID: BMS2038INST; 
eBioscience Ltd., UK), and bone morphogenetic protein-4 (BMP-4) (ID: E-EL-H0012; Elabscience, 
USA).  Inter-assay variability of all kits was found to be <5 %. 
Serum IgG anti-oxLDL levels were measured by coating a 96 well plate with copper-oxidised LDL 
at 5 μg/ml in PBS and incubating overnight at 4 °C on a rocker. The plate was subsequently 
washed four times with 200 μl PBS per well. The wells were blocked for 1 hour with a solution 
containing 5 % BSA (Fisher Scientific) and 0.1 % Tween-20 (Sigma) in PBS (300 μl per well). The 
plate was washed twice, as above, and 200 μl serum samples were added to the coated wells 
and incubated for 2 hours at 37 °C. The wells were washed three times with a PBS / 0.5 % BSA / 
0.1 % Tween-20 solution. 200 μl horseradish peroxidase-conjugated rabbit anti-human IgG 
secondary antibody (Sigma-Aldrich, UK) was added to each well (1:2000 dilution in blocking 
buffer) and the plate was incubated for 30 minutes at 37 °C. The plate was washed 5 times and 
90 μl TMB was added to each well, with a subsequent 20 minute incubation at 37 °C. The 
reaction was stopped by the addition of 0.16M sulphuric acid. Absorbance at 450 nm was 







4.3.4 Measurement of low-density lipoprotein levels 
Serum LDL measurements were conducted by the ViaPath laboratory at Guy’s and St Thomas’ 
NHS Foundation Trust. OxLDL levels stated in the results section of this chapter are expressed 
as the oxLDL/LDL ratio to adjust for serum LDL levels, as per commonly accepted practice 285 
286. 
 
4.3.5 Monocyte isolation: 
Monocytes were isolated from the peripheral blood mononuclear cells (PBMCs) of subjects using 
a commercially available pan-monocyte isolation kit for magnetic cell sorting (ID 130-096-537; 
Miltenyi Biotec, UK) and a magnet separator kit (MiniMACS Starting Kit ID: 130-090-312; 
Miltenyi Biotec, UK). 
A buffer solution (pH 7.2) was prepared with PBS, 0.5 % BSA, and 2 mM EDTA, and this was kept 
at 4 °C. To prevent capping of antibodies on the cell surface and non-specific cell labelling, pre-
chilled solutions were used throughout the experiment.   
4 ml whole blood was collected in a vacuum-tube coated with EDTA. The blood was diluted with 
an equal volume of 0.9 % saline. 6 ml diluted blood was layered over 3 ml LymphoprepTM solution 
(ID: 07851; STEMCELL Technologies, Canada) in a 15 mm centrifuge tube. The blood was 
centrifuged at 800 x g for 20 minutes at 20 °C to separate the blood components. The PBMC top 
layer was aspirated and transferred to a falcon tube. The cell suspension was centrifuged again 
at 300 x g for 10 minutes at 4 °C; the supernatant was removed and the cell pellet retained.  
The cell pellet was re-suspended in 30 µL of buffer. 10 µL FcR Blocking Reagent was added, along 
with 10 µL of Biotin-Antibody Cocktail. The solution was vortexed and incubated for 5 minutes 
at 4°C. 30 µL of buffer was added, followed by 20 µL of Anti-Biotin MicroBeads. The solution was 
vortexed and incubated for a further 10 minutes at 4 °C.  
The MACS magnetic column was attached to the MACS separator magnet. The column was 
rinsed with 500 µL of buffer and the cell suspension was applied onto the column. The flow-
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through containing unlabelled cells, representing the enriched monocyte fraction, was 
collected. 
The column was rinsed 3x with 500 µL buffer and the unlabelled cells were again collected and 
added to the previous yield.  
 
4.3.6 Stimulation of whole blood and isolated monocytes 
MDA-modified LDL (ID: STA-212; Cell Biolabs, Inc., USA) at a concentration of 100 μg/ml was 
used to stimulate whole blood and isolated monocytes.  
A mouse monoclonal fragment antigen binding (F(ab')2) antibody directed against human CD16 
cells (1mg/ml when reconstituted; Anti-CD16 human mAb 3G8 F(ab')2; ID: ANC165-520; Caltag, 
UK) was used at saturating concentrations 287 288 to specifically block CD16 Fc γ receptor 
activation and thus delineate CD16-dependent pathways.  
 
Whole blood: 
2 ml whole blood was collected in a vacuum-tube coated with EDTA. Four 250 μl aliquots of each 
blood sample were prepared as follows:  
  
Tube 1: Control sample – 250 μl whole blood 
Tube 2: 250 μl whole blood plus 12.5 μl MDA-LDL 
Tube 3: 250 μl whole blood plus 2.5 μl F(ab’)2  
Tube 4: 250 μl whole blood plus 12.5 μl MDA-LDL and 2.5 μl F(ab’)2  
 
The tubes were incubated at 37 °C for 60 minutes and then immediately processed for 







Monocytes were isolated, as per Section 4.3.5. Four monocyte suspension aliquots from each 
donor were prepared as follows: 
 
Tube 1: Control sample – 250 μl monocyte suspension 
Tube 2: 250 μl monocyte suspension plus 12.5 μl MDA-LDL 
Tube 3: 250 μl monocyte suspension plus 2.5 μl F(ab')2  
Tube 4: 250 μl monocyte suspension plus 12.5 μl MDA-LDL and 2.5 μl F(ab')2 
 
The tubes were incubated at 37 °C for 60 minutes and then immediately processed for RNA 
isolation. 
 
4.3.7 Ribonucleic acid isolation 
RNA was isolated from whole blood samples (collected in vacutainer tubes coated with EDTA to 
prevent coagulation) using a commercially available QIAamp RNA Blood Mini Kit (ID 52304; 
Qiagen) as per the manufacturer’s protocol. When isolated monocytes were used in place of 
whole blood, the protocol began from Step 2. 
 
Step 1: Cell lysis 
500 μl whole blood was mixed with 2500 μl erythrocyte lysis buffer in a falcon tube, and 
incubated on ice for 20 minutes. The tube was vortexed twice during incubation. The sample 
was then centrifuged at 400 x g for 10 minutes at 4 °C and the red cell supernatant was then 
discarded to retain the leucocyte pellet. 1000 μl erythrocyte lysis buffer was then added and the 
tube was vortexed to re-suspend the cells. Centrifugation was performed for the second time, 
at 400 x g for 10 minutes at 4 °C and the red cell supernatant was discarded.  
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350 μl RLT buffer (a buffer containing a high concentration of guanidine isothiocycanate to aid 
the binding of RNA to the silica membrane of the spin columns) was added to the pelleted 
leucocytes and repeatedly pipetted to re-suspend the cells.  
 
Step 2: Homogenisation 
The lysate was pipetted into a QIAshredder spin column in a 2 ml collection tube and centrifuged 
at 10,000 x g for 2 minutes at 4 °C. The spin column was discarded and the homogenised lysate 
was retained. 350 μl 70 % ethanol was added to the collection tube, and was mixed by repeated 
pipetting. The sample was pipetted into a new QIAamp spin column in a 2 ml collection tube and 
was centrifuged at 10,000 x g for 2 minutes at 4 °C. 
 
Step 3: DNA digestion 
Deoxyribonuclease (DNase) stock solution was prepared by dissolving lyophilized a DNase I 
(1500 Kunitz units) vial (ID 79254, Qiagen) in 550 µl nuclease-free water. 350 µl RW1 buffer (a 
wash buffer containing guanidine salt and ethanol that removes biomolecules from the silica 
membrane whilst retaining RNA molecules was added to the QIAamp spin column. The tube was 
centrifuged at 10,000 x g for 15 seconds at 4 °C.  
10 µl DNase I stock solution was added to 70 µl RDD buffer (a buffer that facilitates on-column 
digestion of DNA) in a 1.5 ml microcentrifuge tube. The tube was gently mixed and then 
centrifuged at 10,000 x g for 5 seconds to collect residual fluid from the sides of the tube. The 
80 µl DNase I mix was pipetted directly onto the QIAamp spin column membrane and placed on 
the benchtop for 15 minutes at room temperature. 
350 µl RW1 buffer was added to the spin column, and this was then centrifuged at 10,000 x g 






Step 4: RNA extraction 
The spin column was placed in a new 2 ml collection tube. Ethanol was added to the RPE buffer 
(a buffer to remove residual traces of salts from previous buffers) that was provided with the 
kit. 500 µl of RPE buffer was pipetted into the spin column, which was then centrifuged at 10,000 
x g for 15 seconds at 4 °C. The flow-through and collection tube were discarded. 
500 µl RPE buffer was added to the spin column, which was then centrifuged at 20,000 x g for 3 
minutes at 4 °C. The collection tube and filtrate were discarded and the spin column was placed 
in a new collection tube, which was then centrifuged at 20,000 x g for 1 minute at 4°C to prevent 
any RPE buffer from being retained on the membrane. The spin column was transferred into a 
1.5 ml microcentrifuge tube and 50 µl nuclease-free water was pipetted directly onto the 
membrane. The tube was centrifuged at 8000 x g for 1 minute at 4 °C to obtain the RNA yield.  





4.3.8 Copy deoxyribonucleic acid synthesis  
cDNA was synthesised from the RNA samples by using a RevertAid H Minus First Strand cDNA 
Synthesis Kit (ID: K1631; Thermo Fisher Scientific, UK) as per the manufacturer’s protocol. 
 
Step 1: First strand cDNA synthesis 
Aliquots of each RNA sample were diluted with nuclease-free water to achieve a uniform 
concentration in a sterile, nuclease-free microcentrifuge tube, at a total volume of 11.5 µl and 
were kept on ice. 1.5 µl random hexamers were subsequently added to anneal to 
complementary sites on the RNA, thus serving as primers for cDNA synthesis.  
4 µl 5x reaction buffer (250 mM Tris-HCl (pH 8.3), 250 mM KCl, 20 mM MgCl2, 50 mM DTT) was 
added to the tube, followed by 1 µl RiboLock RNase Inhibitor (20 U/ µl). 2 µl of 10 mM 
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deoxynucleotide mix was then added, followed by 1 µl RevertAid H Minus M-MuLV reverse 
transcriptase (200 U/µl), bringing the total volume in each tube to 20 µl. The tubes were mixed 
gently and subsequently centrifuged.  
A 96 well thermal cycler (2920 Thermal Cycler; Applied Biosystems, UK) was used to conduct the 
polymerase chain reaction. The cycler was set to incubate the RNA for 5 minutes at 25 °C 
followed by 60 minutes at 42 °C. The cDNA synthesis reaction was terminated by heating the 
tubes to 70 °C for 5 minutes. 
 
Step 2: Real-time quantitative polymerase chain reaction amplification of cDNA 
A panel of genes related to biomolecular pathways involved in the activity of the adaptive 
immune system and synthesis of osteogenic molecules were studied, including BMPs, matrix 
metallopeptidases (MMPs) and the NLRP3 gene component of the inflammasome oligomer. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a housekeeping gene. Primer 













Table 4.1: Sequence of primers used for polymerase chain reaction 
 
Gene Forward primer (5’ – 3’) Reverse primer (5’ – 3’) 
GAPDH CAAGGTCATCCATGACAACTTTG GGGCCATCCACAGTCTTCTG 
CD16 GACAGTGTGACTCTGAAG GCACCTGTACTCTCCAC 
IL-1β ACAGATGAAGTGCTCCTTCCA GTCGGAGATTCGTAGCTGGAT 
IL-8 ACCGGAAGGAACCATCTCAC GGCAAAACTGCACCTTCACAC 
Inflammasome (NLRP3) TGAAGAAAGATTACCGTAAGAAGTACAGA GCGTTTGTTGAGGCTCACACT 
BMP-2 CCCCCTACATGCTAGACCTGT CACTCGTTTCTGGTAGTTCTTCC 
BMP-4 TGGTCTTGAGTATCCTGAGCG CACTCGTTTCTGGTAGTTCTTCC 
Caspase-1 TGCCTGTTCCTGTGATGTGG CTGGGAAGAGGTAGAAACATC 
c-Myc GGCGAACACACAACGTCTTG TCCGTTTTAGCTCGTTCCTC 
Cyclin D1 GATGGCGATCGTCCTGTCAT ACAGGCCGCTACAAGAAACA 
Beta catenin GTCAGCTCGTGTCCTGTGAA TTCAGGTACCCTCAGGCCC 
Netrin-1 (full length) CCCGGACTTTGTCAATGC GTTGTTGAGGTCGGRGAGGA 
Netrin-1 (truncated) ACTATGCCGTCCAGATCCAC TCTTGAGGGGCTTGATTTTG 
MMP-2 TATTTGATGGCATCGCTCAG GCCTCGTATACCGCATCAAT 











2 µl of the first strand cDNA synthesis reaction mixture (to be used as template for the 
subsequent polymerase chain reaction (PCR) step) was pipetted directly into each of the wells 
of a Rotor-Disc 100 plate (Qiagen). An 8 µl mixture containing 5 μl SYBR green mix (a nucleic acid 
fluorophore stain), 2.6 μl nuclease-free water, 0.2 μl of the relevant forward primer, and 0.2 μl 
of the relevant reverse primer was subsequently added to each well. The disc was sealed using 
a Rotor-Disc Heat Sealer (Qiagen).  
DNA was amplified using a real-time quantitative PCR cycler (Rotor-Gene Q; Qiagen), with 50 
cycles of the following thermal protocol, following an initial 10 minutes held at 95 ºC: 
 
1) 95 ºC for 10 seconds 
2) 58 ºC for 20 seconds 
3) 72 ºC for 10 seconds  
 










































































































































































4.3.9 Evaluation of monocyte lipid content 
Monocyte subsets were identified according to their surface expression of CD14 and CD16 using 
fluorochrome conjugated antibodies, as per methodology described in Chapter Two. Dr 
Gabriella Passacquale characterised the lipid content within each subset of monocytes by flow 
cytometry, using Nile red (9-diethylamino-5-benzo[α]phenoxazinone) staining to localise and 
quantify intracellular lipid droplets.  
 
4.3.10 Statistical analysis 
Statistical analyses were performed using GraphPad Prism (version 6.0) software. Parametric 
data are expressed as the mean ± SEM, whilst non-parametric data are expressed as the median 
with IQR. ANOVA was used to compare percentage variation of each study variable between the 
4 treatment groups in the influenza immunisation study. Baseline and post-treatment values 
were compared within each group using a paired parametric or non-parametric test as 
appropriate. ANCOVA was used to compare percentage variation of each study variable 




4.4.1 There is an inverse relationship between circulating oxidised low-density lipoprotein and 
IgG anti-oxidised low-density lipoprotein levels 
A highly significant reduction in baseline circulating oxLDL levels of 10.75 % post-immunisation, 
from 819.00 ± 38.68 ng/ml to 730.20 ± 49.37 ng/ml (p = 0.0015) was observed in participants 
who were not treated with anti-platelet agents. In those taking aspirin 300 mg (Group 1), 
circulating oxLDL levels fell by 10.50 %, from 735.8 ± 39.99 to 658.5 ± 27.68 (p = 0.03), whilst 
remaining unchanged in those taking aspirin 75 mg (Group 2). In participants taking clopidogrel 
(Group 3), oxLDL levels exhibited a non-significant reduction of 15.37 % from 852.70 ± 82.16 
ng/ml to 721.60 ± 74.10 ng/ml (p = 0.079), Figure 4.2. It is worth noting that although the 
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baseline level of oxLDL in this group was apparently higher than other groups, there were no 
statistically significant differences between groups for baseline levels of either oxLDL, IgG anti-
oxLDL. 
There were no significant changes in levels of IgG anti-oxLDL among all groups following 
immunisation (Figure 4.3). The levels of circulating IgG anti-oxLDL measured at baseline (before 
immunisation) in the total population were inversely related to baseline oxLDL levels (p = 0.0011, 
r = -0.4207); Figure 4.4. This inverse relationship was preserved post-immunisation, with a 
negative linear correlation between the percentage change in oxLDL and the percentage change 











































Figure 4.2: Change in oxidised low-density lipoprotein levels post-immunisation 
Panel A shows the absolute values of oxLDL pre- and post-immunisation. Panel B shows the percentage 






























Figure 4.3: Change in IgG anti-oxidised low-density lipoprotein levels post-immunisation 
Panel A shows the absolute values of IgG anti-oxLDL pre- and post-immunisation. Panel B shows the 





























































































































Figure 4.4: Correlation between percentage change in oxidised-low density lipoprotein and 
IgG anti-oxidised low-density lipoprotein levels  
Panel A shows the correlation between baseline levels of oxLDL and anti-oxLDL IgG. Panel B shows the 
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4.4.2 In the absence of inflammation, circulating IgG anti-oxidised low-density lipoprotein 
levels are inversely related to the percentage of CD16+ monocytes 
As described in Chapter Two, the percentage of CD16+ monocytes (specifically, the 
CD14highCD16+ subtype) increased significantly post-immunisation in non-anti-platelet treated 
(Group 4) participants. There was a strong negative correlation between baseline IgG anti-oxLDL 
levels and the baseline total percentage of CD16+ monocytes in the total population (p = 0.0038, 
r = -0.4280), whilst anti-oxLDL IgG was positively correlated with the percentage of CD16- 
monocytes (p = 0.0079, r = 0.3998); Figure 4.5. No correlation was found between either oxLDL 
or anti-oxLDL IgG and the marker of platelet activation, P-selectin, however.  
Baseline levels of oxLDL were not related to monocyte subtype percentage. There was no 
significant correlation between post-immunisation oxLDL levels and CD16+ monocytes in the 
untreated group (p = 0.8929, r = -0.103); nor was there any correlation between oxLDL levels 






























Figure 4.5: Correlation between levels of IgG anti-oxidised low density lipoprotein and CD16- 
/ CD16+ monocytes 
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4.4.3 CD14highCD16+ monocytes have a higher intracellular lipid content than CD16- monocytes 
Evaluation of the in vivo lipid content of the different subsets of monocytes revealed that 
CD14highCD16+ cells are those with the higher amount of intracellular lipid droplets, thus 
suggesting their more avid phagocytosis of oxLDL; see Figure 4.6. 
 
4.4.4 Exposure of monocytes to oxidised low-density lipoprotein leads to induction of the 
inflammasome / IL-1β pathway 
In view of the fact that CD16 is expressed on both monocytes and CD56dim peripheral blood 
natural killer cells, I performed PCR analysis of RNA from both isolated monocytes and whole 
blood in each sample. Results did not differ significantly between the two methods, indicating 
that the observed CD16-dependent outcomes were primarily related to monocytic CD16.  
No association was identified between levels of circulating anti-oxLDL IgG and hs-CRP 18, nor was 
there a relationship between anti-oxLDL IgG and MPO, a peroxidase enzyme that is stored in 
neutrophil granules and is a key part of the inflammatory response. Baseline levels of IgG anti-
oxLDL were, however, linearly correlated with levels of the pro-inflammatory, inflammasome-
mediated cytokines, IL-1β (p = 0.0016, r = 0.4532) and IL-6 (p = 0.0044, r = 0.4902), as measured 
using the Luminex® technique; Figure 4.7. The relationship between anti-oxLDL IgG and the 
inflammasome pathway was further explored by stimulating isolated monocytes with MDA-LDL, 
which led to induction of IL-1β and NLRP3 inflammasome genes (at a rate of 2.30 ± 0.55 and 1.94 
± 0.36 times that of monocytes not exposed to MDA-LDL respectively). An amplification in IL-1β 




4.4.5: Malondialdehyde-modified low-density lipoprotein stimulates CD16-dependent gene 
induction of osteogenic molecules 
Vascular calcification is directly related to plaque burden 289 290 and many studies have associated 
LDL levels with the presence and severity of vascular calcification 289 291. It has been widely 
demonstrated that inflammasome activation is required in the formation of intra-vessel calcium 
deposits 292 293 and calcified arteries express various regulatory factors, including BMPs 289. To 
further assess the immunomodulatory action of CD16 in the signal transduction pathways 
triggered by MDA-LDL, we stimulated isolated monocytes with MDA-LDL and measured levels 
of osteogenic markers. We found that exposure to MDA-LDL led to induction of BMP-4 RNA 
expression in monocytes at a rate of more than 4 times (4.05 ± 1.95) that of monocytes that 
were not exposed to MDA-LDL. Blockade of CD16 using the anti-CD16 F(ab’)2 inhibited BMP-4 
induction, indicating that the pathway was CD16-dependent; Figure 4.8. 
In light of this finding, BMP-4 protein levels were measured in the stored serum samples 
obtained from the vaccination study using the ELISA technique. The rise in CD16 and reduction 
in oxLDL in the untreated group post-immunisation was found to also be paralleled by a 
significant decrease in BMP-4 levels by 13.5 %, from 1270 (IQR: 1175 – 1563) pg/ml to 1151 (IQR 
852 – 1341) pg/ml (p = 0.0110). All anti-platelet therapy regimens tested counteracted this 
























Figure 4.6: Characterisation of lipid content within monocytes 
Panel A shows a typical monocyte phenotype profile using flow cytometry to sort the cells based on 
their CD14 and CD16 surface markers. Panel B shows the same cells now sorted based on their uptake 


























































Figure 4.7: Correlation between levels of IgG anti-oxidised low-density lipoprotein and 
inflammasome-mediated cytokines 
Panels A and B show the correlation between IgG anti-oxLDL and IL-1β and IL-6 respectively, as 
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Figure 4.8: Gene induction following in vitro stimulation of monocytes with 
malondialdehyde-modified low density lipoprotein 
Stimulation of isolated monocytes with MDA-LDL in vitro led to induction of BMP-4 (A), IL-1β (B) and 
NLRP3 (C). Blockade of CD16 using anti-CD16 F(ab’)2 (10 μg/ml) inhibited gene induction of BMP-4 
only, either with or without MDA-LDL. Data were obtained by quantitative real-time quantitative PCR 















Figure 4.9: Bone morphogenetic protein 4 levels pre- and post-immunisation 





It has been hypothesised that the FC  receptor, CD16, may regulate oxLDL phagocytosis, as part 
of the homeostatic immunological response 294. I have explored the potential role of CD16+ 
monocytes in modulating levels of oxLDL and IgG anti-oxLDL autoantibodies in the context of an 
immunogenic response to influenza immunisation, which is known to generate systemic 
inflammation 30. Immunisation has been shown earlier in this thesis (see Chapter Two) to induce 
a rise in CD16+ monocytes, specifically the CD14highCD16+ subset, in the absence of lipid profile 
modifications. 
I found that in healthy subjects, the circulating level of IgG anti-oxLDL was inversely related to 
both circulating oxLDL concentration and the percentage of C16+ monocytes, in keeping with 
the hypothesis that C16+ cells act as scavengers for anti-oxLDL IgG antibodies, forming 
immunocomplexes with modified lipoproteins.  
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In the presence of mild, systemic inflammation induced by influenza immunisation, there was 
an expansion of the CD16+ monocyte subset that was paralleled by a downregulation of oxLDL 
in the non-anti-platelet treated participants, possibly indicating that a higher burden of 
inflammation leads to greater recruitment of CD16 cells to mediate the clearance of pro-
immunogenic molecules, such as oxLDL. Although there was no significant correlation between 
CD16 positivity within monocytes and oxLDL levels post-immunisation in this untreated group, 
the fact that the sample size was small (n = 10) and the reduction in oxLDL, although consistent, 
was small may account for this lack of significance.  
Of note, the post-immunisation attenuation in oxLDL levels observed in the untreated 
participants (Group 4) was also present in those taking aspirin 300 mg daily (Group 1) and 
clopidogrel (Group 3), but not in those on aspirin 75 mg daily (Group 2) despite all treatment 
groups having stable levels of CD16+ monocytes. The observed changes in oxLDL among all 
groups were contrasted by apparently opposite changes in anti-oxLDL IgG levels, although the 
increase in IgG anti-oxLDL did not reach significance. Despite the absence of a significant 
increase in IgG anti-oxLDL post-immunisation, the percentage reduction in circulating oxLDL 
levels was linearly related to the change from baseline of IgG antibodies post-immunisation, 
supporting the theory that IgG anti-oxLDL mediates the clearance of immunogenic lipoproteins 
in the presence of inflammation, and this process may be linked to CD16.  
Furthermore, the reduction in oxLDL observed in two treatment groups (aspirin 300mg daily and 
clopidogrel), may be attributed to the anti-platelet effect of the drugs inhibiting activated 
platelet-induced oxidation of LDL, in the context of acute inflammation 295. Activated platelets 
oxidise LDL molecules via NOX2 activation in the presence of oxidative stress 296 and the 
observed reduction in oxLDL in participants taking either aspirin 300 mg daily or a clopidogrel 
regime (including a loading dose) may represent effective platelet inhibition and thus reduced 
oxidation of lipoproteins. The fact that there was no reduction in oxLDL in the participants taking 
aspirin 75 mg daily (Group 2) could point towards a reduced effectiveness in achieving platelet 
inhibition with the lower dose of aspirin. Indeed, I previously discussed, in Chapter Two of this 
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thesis, the fact that aspirin 75 mg may be less efficacious than aspirin 300 mg both at reducing 
soluble the platelet-activation marker, P-selectin, and at modulating the phenotype of 
circulating monocytes in this model of inflammation 18. 
Evaluation of the in vivo lipid content of the different subsets of monocytes identified that 
CD14highCD16+ cells are those with the higher amount of lipid droplets, suggesting their more 
avid phagocytosis of oxLDL compared with other monocyte subtypes - as other authors have 
previously observed and reported to be independent from conventional scavenger receptors 294.  
As there is a higher number of circulating CD16+ monocytes present in acute inflammation, this 
could also explain the reduction in oxLDL in the untreated group. 
I subsequently assessed the immunomodulatory action of CD16 in the signal transduction 
pathways triggered by MDA-LDL. This latter was found to directly activate the CD16 Fc  receptor 
and to stimulate CD16-dependent gene induction of the osteogenic molecule, BMP-4. In the 
setting of immunisation-induced inflammation, the rise in CD16+ monocyte percentage that was 
associated with the reduction in oxLDL in the untreated group was paralleled by a reduction in 
BMP-4, whilst anti-platelet therapy counteracted the changes in both CD16 and BMP-4. These 
data suggest that CD16 plays a role in the regulation of monocyte/macrophage osteogenic 
pathways in response to MDA-LDL. Given the emerging role of BMPs, particularly BMP-2 and 
BMP-4, in promoting vascular calcification 297 298, modulation of these pathways via CD16 may 
provide a target in the prevention of chronic calcific arteriopathy.  
MDA-LDL also activated the inflammasome pathway, which controls IL-1β and thus IL-6 
production, although this was found to be in a CD16-independent manner. Of note, a slight 
amplification of the IL-1β gene occurred in the presence of CD16 blockade, indicating that CD16 
can cross-block MDA-LDL from binding to other receptors. In Chapter Two of this thesis, I 
previously identified a tendency towards a reduction in circulating IL-1β levels in the presence 
of CD16+ monocyte expansion, although this did not reach statistical significance, which was not 
present in those taking anti-platelet therapy 18.  CD16 is a natural ligand of the CR3 
(CD11b/CD18) receptor 299 that mediates the activation of the inflammasome pathway induced 
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by cholesterol crystals and modified LDL, which is not only implicated in foam cell formation, but 
is also required for T and B cell stimulation and consequent antibody production 300-302. Further 
research is required to establish whether similar changes in inflammasome activation are 
present in chronic inflammatory disease, such as atherosclerosis, and whether reduced CD16 
activity in this context can modulate the accumulation of oxLDL and IgG anti-oxLDL 
autoantibodies and thus modify the amplification of the adaptive immune response mediated 
by the inflammasome pathway. 
 
4.6 Conclusion 
CD16 is an FC γ receptor that is activated upon binding to IgG and may mediate the clearance of 
IgG antibodies against oxLDL. The present data indicate that CD16+ monocytes may regulate the 
clearance of oxidised lipoproteins and their systemic accumulation, possibly through the 
internalisation of circulating oxLDL / IgG immunocomplexes mediated by Fc γ receptors, 
including CD16. Furthermore, CD16 is directly activated by MDA-LDL and up-regulation of this 
biomolecular pathway (consequent to either reduced clearance of immunocomplexes via Fc γ 
receptors and/or abnormal synthesis of oxLDL) may be implicated in the induction of osteogenic 






































5.1 Introduction  
Until recent years, the pathophysiology of atherosclerosis has principally been described as a 
disorder of lipid storage, and pharmacological therapies have thus primarily been targeted at 
reducing serum cholesterol. As the underlying cellular mechanisms of atherogenesis have been 
gradually elucidated, it has become apparent that chronic inflammation is a key mediator of the 
processes that lead to plaque formation. 
This thesis has explored the potential role of several novel inflammatory biomarkers in the 
pathways governing the development of atherosclerosis and its complications, and provides 
evidence that anti-platelet agents may be beneficial in limiting further disease progression, 
through both their anti-platelet and anti-inflammatory actions.  
 
5.2 Intermediate monocytes as a potential therapeutic target 
The primary focus of this PhD was to assess the role of CD14highCD16+ monocytes in the context 
of an underlying inflammatory process and to ascertain whether the COX inhibitor, aspirin, or 
P2Y12 receptor inhibitors are able to modify the circulating levels of these pro-inflammatory 
monocytes. 
An important finding from my work was that anti-platelet therapy, namely aspirin, clopidogrel 
or ticagrelor, was capable of preventing a rise in circulating CD14highCD16+ monocytes in the 
presence of an inflammatory stimulus. The data obtained from this study was in accordance with 
previous work demonstrating an expansion in the intermediate monocyte subset in the 
presence of acute, systemic inflammation 31, and I have been able to show that all of the tested 
anti-platelet agents were able to counteract this response.  
Part of the rationale behind choosing both P2Y12 inhibitors and aspirin was to ascertain whether 
attenuation of the CD14highCD16+ subgroup was occurring primarily due to an anti-platelet 
effect, an anti-inflammatory effect, or a combination of these factors. The fact that all three 
treatments were effective in suppressing the rise in intermediate monocytes suggests that the 
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effect was primarily related to inhibition of platelet function, particularly as there was no 
reduction in hs-CRP levels post-immunisation in any of the treatment groups.  
Many studies have linked CD14highCD16+ monocytes to increased cardiovascular events 22 225 and 
previous work has shown a correlation between a reduction in this monocytic subset, and a 
decrease in subclinical atherosclerosis in obese patients undergoing rapid weight loss 189 but 
there is no evidence to date that a reduction in circulating CD14highCD16+ monocyte levels, 
without modifying cardiovascular risk factors, will result in attenuation of atherosclerosis. 
Having shown that anti-platelet therapy can suppress the rise in intermediate monocytes in the 
context of acute inflammation, the next step in this area of our research will be to assess 
whether anti-platelet therapy is capable of directly attenuating circulating intermediate 
monocytes in patients with atherosclerotic plaque disease, which could potentially indicate a 
role for these drugs in the long term management of atherosclerosis.  
 
5.3 The role of anti-platelet therapy in modifying biomarkers of cardiovascular risk 
Following on from the above research where I demonstrated that anti-platelet therapy can 
attenuate pro-inflammatory monocyte levels, I went on to assess whether these agents can 
similarly modify other novel biomarkers of cardiovascular risk. Data from the last 15 years 
suggests that traditional indicators of cardiovascular risk, such as LDL, may soon be superseded 
by measures of inflammation 303. Hs-CRP, as a non-specific marker of inflammation, now forms 
part of the standard assessment of cardiovascular risk in asymptomatic adults in the USA 304.  
In view of the emerging role of netrin-1 in both inflammatory pathways and as a novel 
therapeutic target in cardiovascular disease, we selected this protein for further assessment. A 
clinical study previously undertaken by other members of our research group involved 
administering aspirin for 28 days to healthy subjects 254 – there was frozen serum available from 
this cohort and I measured netrin-1 levels in these samples. I identified a small but consistent 
decline in netrin-1 levels in these healthy people following aspirin therapy. Previous work had 
shown that netrin-1 levels fall in the presence of acute inflammation 217 and thus these findings 
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were somewhat unexpected. I subsequently confirmed a reduction in netrin-1 levels in 
participants exposed to an inflammatory stimulus and was ultimately able to establish the 
presence of an interaction between netrin-1 and COX, possibly through COX-derived 
prostaglandin E2. Netrin-1 plays a complex role in leucocyte recruitment and, whilst this work 
has shown that it is possible to modify netrin-1 levels using anti-platelet therapy, whether 
pharmacological up- or downregulation of netrin-1 levels could have potential benefits in a 
clinical setting has yet to be determined.   
Having demonstrated the ability to manipulate the circulating levels of intermediate monocytes 
with anti-platelet agents, I then performed further experiments to determine whether this could 
induce changes in the levels of circulating oxLDL and IgG anti-oxLDL. Although I was unable to 
show a direct link between levels of these two key biomarkers of atherogenesis and monocytic 
CD16 positivity, the data did indicate that CD16+ monocytes may regulate the clearance of 
oxidised lipoproteins, and I have speculated that this may be via the internalisation of circulating 
oxLDL / IgG immunocomplexes mediated by CD16. In view of the differing effects of low-dose 
(75 mg daily) aspirin compared with higher doses of aspirin and with clopidogrel, I hypothesised 
that the latter two therapies were capable of inhibiting activated platelet-induced oxidation of 
LDL but a direct link was not proven and further work will need to be done to ascertain whether 
oxLDL levels can be modified by these drugs in the context of cardiovascular disease. 
 
6.4 Future work 
In view of the fact that atherosclerosis is a chronic, inflammatory process, my PhD has thus far 
investigated whether anti-platelet agents are able to modify the progression of atherogenesis 
via their anti-inflammatory effects.  Having established further information regarding some of 
the complex pathways involved in mild inflammation in healthy people, our next objective will 
be to determine whether the hypothesis that platelet inhibition, achieved via administration of 
anti-platelet drugs, reduces the activation of monocytes and the upregulation of pro-
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inflammatory CD14highCD16+ monocyte expression in patients with cardiovascular risk factors or 
indeed with established cardiovascular disease is correct. 
We are currently in the early stages of conducting a clinical study with the aim of  identifying 
whether anti-platelet therapy is capable of attenuating the expansion of circulating 
CD14highCD16+monocytes in patients with chronic inflammation related to atherosclerosis and, 
if so, whether this might be a potentially useful therapeutic strategy. The study design and 
preliminary data are discussed in Appendix One. 
Once the study proceeds, I hope to produce data that further elucidates the mechanisms 
underlying the attenuation of monocyte CD16+ acquisition following anti-platelet therapy by 
measuring additional biomarkers and conducting platelet function assays. If anti-platelet 
therapy is indeed capable of modifying the circulating monocyte phenotype in patients with 
cardiovascular risk factors, this could have important implications for the pharmacological 
management of atherosclerosis. 
Furthermore, when conducting the clinical study described above I will measure levels of netrin-
1 in patients with established cardiovascular risk factors with the aim of establishing whether 
their baseline levels differ from that of the general population and, if so, whether anti-platelet 
agents are capable of normalising this. Measurement of additional markers of COX function may 
enable a better understanding of how netrin-1 interacts with prostanoids and, given the proven 
role of netrin-1 in monocyte trafficking, could contribute to the development of future targeted 
therapies with the aim of modulating netrin-1 and thus leucocyte migration.  
Additionally, samples from patients with cardiovascular risk or with established atherosclerosis 
will allow us to establish whether alterations in baseline inflammasome activation are present 
in these subjects and to further study the interactions between CD16 and oxLDL / IgG anti-oxLDL 
antibodies. Such data could facilitate the ultimate development of techniques to modify the 
amplification of immune responses that lead to atherogenesis.  
In the future, it is hoped that the work described here may lead to a large-scale long-term 
longitudinal study to definitively ascertain the effect of anti-platelet therapy on atherosclerosis 
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progression. Identification of the molecular mechanisms underlying inflammation-driven 
monocytic CD16+ acquisition and their subsequent interactions with other markers of 
inflammation, including netrin-1 and oxLDL, may contribute to our understanding of the 
pathophysiology underlying atherogenesis as well as novel pharmacological options to interrupt 
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Appendix 1.1 Study design 
This study will aim to recruit up to 60 patients with cardiovascular risk factors but no prior 
cardiovascular events from hypertension clinics at Guy's and St Thomas' NHS Foundation Trust. 
Those with underlying cardiovascular risk factors, otherwise healthy, with no prior 
cardiovascular event and asymptomatic for atherosclerotic disease will be screened for 
recruitment. 
Patients will have blood samples taken at baseline and then receive 28 days of treatment with 
aspirin 75 mg once daily, at which point they will undergo further blood sampling. Participants 
will additionally be assessed for increased carotid IMT and/or carotid atherosclerotic plaque 
disease as diagnosed on carotid ultrasound. Those with evidence of carotid plaques will be 
advised to continue on lifelong aspirin and their general practitioners will be informed. 
Carotid ultrasonography will be performed by Dr Ben Yu Jiang at the Clinical Research Facility of 
St Thomas’ Hospital. Carotid IMT will be measured by ultrasonography (Accuson Sequoia 512 
machine with an 8-MHz transducer). IMT is taken as the distance between the blood / intima 
borderline and the media/adventitia borderline, and evaluated on the wall of the common 
carotid arteries bilaterally, specifically in the distal 1 cm of the artery just proximal to the bulb. 
Mean carotid IMT will be measured using a semi-automated computer analysis system, and 
confirmed by taking the mean of three manual readings at 20mm intervals along the CCA. Mean 
values of IMT in the anterior and posterior walls of both arteries are to be recorded for analysis. 
Blood samples will be collected as described in Section 2.3.3. A whole blood sample in EDTA will 
be sent to the Viapath laboratory at Guy's and St Thomas' NHS Foundation Trust to measure 
HbA1c levels and a full blood cell count. Similarly, a serum sample will be sent to Viapath to 
measure renal function, liver function, a cholesterol profile and CRP. I will retain serum and 
plasma aliquots for future use, the preparation of these samples is detailed in Section 2.3.3.  
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In order to assess monocyte phenotype, whole blood will be immunostained, as detailed in 
Section 2.3.4, with the following antibodies: PE-mouse anti-human CD14 (BD Bioscience), 5 FITC-
conjugated anti-human CD16 (BD Bioscience), APC-mouse anti-human CD86 (BD Bioscience). 
The immunostained samples will be analysed using a BD FACSCalibur (BD Bioscience) flow 
cytometer to determine monocyte subset distribution. A total of 50,000 leucocyte events are to 
be acquired and post-acquisition analysis will be performed using FlowJo (version 10) software. 
Cells that are positive for CD86 (a pan-monocytic marker) staining will be used to gate for cells 
with a typical monocytic FSC versus SSC profile, and this population will then be analysed based 
on CD14 and CD16 expression, as previously described in Section 2.3.5; Figure 5.1. The minor 
change in the flow cytometry methodology utilising CD86 to improve the quality of monocytic 
gating has been implemented following feedback from experts in the flow cytometry field, who 
explained that by gating for monocytes using CD14 and CD16 only, we would risk including 






























Appendix Figure 1.1: Flow cytometry analysis 
Panel A shows the gating of cells that were positive for the pan-monocytic stain, CD86. These cells were 
then selected from the monocytic group, as identified on the typical FSC vs SSC plot shown in Panel B. 
Finally, this population of cells were then gated into the respective monocyte populations 









ELISA kits to measure the following markers have been purchased: netrin-1 (SEB827Hu, Cloud-
Clone Corp.), PGE2 (ID: MBS007171, MyBioSource, Inc., USA), TXB2 (ID: CSB-E08046h, Cusabio, 
China), VCAM-1 (ID: DVC00, R&D Systems, UK), and ICAM-1 (ID: 850.540.096, Diaclone, France). 
All ELISA experiments will be carried out according to the manufacturer specifications. 
The standard deviation for total pro-inflammatory monocytes measured within a population of 
patients with cardiovascular risk factors and either increased IMT or carotid plaque disease was 
6 % in our pilot data. We therefore calculated a sample size of 20 patients per group for the 
clinical study described above, taking a minimum detectable difference in means between pre- 
and post-treatment of 4 %, with power 0.9 and significance level 0.05. All statistical analyses will 
be performed using GraphPad Prism (version 7.3) software. Parametric data will be expressed 
as the mean ± SEM, whilst non-parametric data will be expressed as the median with IQR. 
ANOVA will be used to compare percentage variation of each study variable between the 3 
treatment groups (aspirin, clopidogrel or untreated) in the study. Baseline and post-treatment 












Participant demographics for the initial four patients recruited into the study are reported in 
Appendix Table 5.1. 
 






  Participant Demographics (n = 4)  
Age (years) 62.00 (53.00 – 73.25) 
Sex 2 male, 2 female 
Smoking history 3 ex-smokers, 1 non-smoker 
BMI (weight kg/ height m2) 32.30 (26.85 – 37.22) 
Systolic blood pressure (mmHg) 158 (140 – 165) 
Diastolic blood pressure (mmHg) 95 (84 – 100) 
WCC (x109/l) 5.25 (4.43 – 6.60) 
CRP (mg/l) 0.5 (0.0 – 1.8) 
Triglycerides (mmol/l) 1.20 (0.51 – 2.34) 
HDL (mmol/l) 1.53 (1.16 – 2.08) 
LDL (mmol/l) 2.44 (1.67 – 2.58) 
HbA1c (mmol/mol) 39.5 (37.5 – 49.0) 





Appendix Table 1.2: Preliminary data on monocyte subsets in hypertension patients  
Monocyte counts are also expressed in percentages rather than absolute cell counts due to a 
discrepancy with the data (results from the first participant that was studied show higher cell count 
values for the three monocytic subtypes due to larger total number of events being recorded for 
analysis). 
 
 CD14highCD16- % CD14highCD16+ % CD14lowCD16+ % 
Hypertension 
patients (n = 4) 
88.70 (83.70 – 92.35) 5.84 (2.34 – 11.84) 1.22 (0.67 – 1.44) 
